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I INTRODUCTION
I.1. Prostate Cancer
Prostate cancer is the leading cause of new cases of cancer and the second 
leading cause of deaths in men in the United States (Table I.1 and I.2). Among men, 
cancers of the prostate, lung and bronchus, and colon and rectum account for about 
50% of all newly diagnosed cancers. Prostate cancer alone accounts for about 28% 
(217,730) of incident cases in men (Table I.1). The incidence of prostate cancer is
age, race, and area dependent. Less than 1% of cases are diagnosed under the age 
of 40, although this may represent an underestimate as screening for disease in 
young men is rare. Prostate cancer is relatively uncommon in Asian populations and 
prevalent in Scandinavian countries, and the highest incidence (and mortality) rates 
known are in African Americans, being ~2-fold higher than in Caucasian Americans.
Estimated new cases of cancer in men, United States, 2010
Prostate 217,730 28%
Lung & bronchus 116,750 15%
Colon & rectum 72,090 9%
Urinary bladder 52,760 7%
Melanoma of the skin 38,870 5%
Non-Hodgkin lymphoma 35,380 4%
Kidney & renal pelvis 35,370 4%
Oral cavity & pharynx 25,420 3%
Leukemia 24,690 3%
Pancreas 21,370 3%
All sites 789,620 100%
Table I.1 Estimated new cases of cancer in men in the United States in 2010 (adapted
from Jemal A, Siegel R, Xu J, Ward E. CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300 [1]).
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Estimated deaths of cancer in men, United States, 2010
Lung & bronchus 86,220 29%
Prostate 32,050 11%
Colon & rectum 26,580 9%
Pancreas 18,770 6%
Liver & intrahepatic bile duct 12,720 4%
Leukemia 12,660 4%
Esophagus 11,650 4%
Non-Hodgkin Lymphoma 10,710 4%
Urinary bladder 10,410 3%
Kidney & renal pelvis 8,210 3%
All sites 299,200 100%
Table I.2 Estimated deaths of cancer in men in the United States in 2010 (adapted from 
Jemal A, Siegel R, Xu J, Ward E. CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300 [1]).
As with other common adenocarcinomas, both numerical and structural 
chromosomal alterations are frequent somatic changes in prostate cancer cells.
Efforts have been made towards the understanding of the molecular mechanisms 
that initiate and lead to progression of this disease. By now, several key molecular
changes were identified. Mouse models revealed the importance of the tumor 
suppressor phosphate and tensin homolog 1 (PTEN) for early tumorigenesis, as 
allelic deletion causes prostate intraepithelial neoplasia (PIN) and invasive cancer at 
later stages [2]. Loss or functional inactivation of PTEN results in excess input from 
PI3K and hyperactivation of the Akt survival pathway. Indeed, hyperactivation of Akt 
has been found in prostate cancer specimens, particularly in advanced stages of the 
disease, as well as in well-established cellular models of prostate cancer, such as 
LNCaP cells. Thus, loss of PTEN affects profoundly the regulation of the lipid based 
secondary messenger system. Indeed, deletion of PTEN obviously hits more 
pathways than PI3K, as constitutively activated Akt leads to PIN, but not invasive 
prostate cancer [3]. Furthermore, the occurrence of pathogenic mutations in PTEN in 
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early prostate cancer may indicate a less favorable outcome, and agents which 
interfere with the PTEN signaling pathway may provide new therapies for prostate 
cancer [4]. Other sites of loss/deletion in prostate cancer mainly occur in the late 
stages of cancer progression. Genetic inactivation of other tumor suppressor genes, 
such as p53, RB1, and p16, is seen most commonly in advanced cases of prostate 
cancer, although non-mutational down-regulation of these genes may frequently 
occur earlier.
The main focus of the research presented in this thesis is on protein kinase C 
(PKC), an important family of serine-threonine kinases widely implicated in cancer.
Several lines of evidence suggest markedly altered mRNA and protein levels of PKC 
isozymes during different stages of prostate cancer progression in rodents and 
humans [5]. Using immunohistochemistry, Cornford et al. demonstrated elevated
levels of PKCα, ε, and ζ in early stage human prostate carcinomas, whereas PKCβ
levels are decreased compared to normal or benign hyperplastic prostate tissues [6]. 
Interestingly, the levels of PKCα mRNA and protein were decreased by 6- to 38-fold 
in androgen-sensitive cells when compared to androgen-insensitive cells [7], 
suggesting a role for PKCα in the transition from an androgen-dependent to an 
androgen-independent state. This is supported by the notion that treatment of male 
adult Wistar rats with the non-steroidal anti-androgen flutamide increased the activity 
of PKCα, as well as membrane translocation of PKCε, and total protein levels of 
PKCα, β, Ι, ε, and ζ compared to non-treated controls. These findings also suggest at 
least in part important roles for these kinases in the development of androgen-
resistance, an event that results in impaired treatment options. Comparing PKC 
protein levels between benign prostatic hyperplasia and prostate cancer tissues from 
patients [8] revealed elevated levels of PKCα, β, ε, and η in prostate cancer tissues, 
in particular PKCε. Also, PKCε has been shown to exert oncogenic functions in 
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prostate and other cancer cell lines by increasing Stat3 Ser727 phosphorylation, 
thereby triggering Stat3-mediated transcription, and subsequently, invasion [9]. In 
addition, other reports indicate a role for PKCε in increased cell survival and
resistance to apoptosis [10, 11]. Taken together, these studies argue for a prominent 
role for PKCε in the initiation and progression of prostate cancer. More recently, PKC 
isozymes have been implicated in certain settings to contribute to epithelial-to-
mesenchymal transition (EMT) in prostate cancer cells [12]. Notably, PKCβ has been 
shown to phosphorylate directly histone H3 at threonine 6, which in turn prevents 
demethylation of methylated histone H3 lysine 4 (H3K4me) by lysine specific 
demethylase 1 (LSD1). In this study, PKCβ co-localized with the androgen receptor 
on promoters of androgen-receptor target genes, and was shown to be critical for 
androgen-dependent activation of transcription in prostate cancer cells [13]. 
The prostate cancer cell line LNCaP expresses the classical PKCα, the novel 
PKCδ and PKCε and the atypical PKCζ. It has been shown that androgen-dependent 
prostate cancer cell lines, such as LNCaP cells, undergo apoptosis upon PKC 
activation following treatment with the phorbol ester phorbol 12-myristate 13-acetate 
(PMA) in contrast to androgen-independent prostate cancer cells, such as PC3 or 
DU145 cells [7, 14]. Fujii et al. have also demonstrated that activation of PKCδ in 
LNCaP cells is responsible for the PMA-induced apoptosis in a caspase-3-
independent manner [14]. Given their importance in prostate cancer biology, PKC 
isozymes, the mechanisms of PKC maturation and activation, and their ligands will 
be discussed in detail (see section I.3). 
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I.2 Apoptosis
I.2.1 General features of apoptosis
Apoptosis is a tightly regulated process in which a cell undergoes 
programmed cell death without disrupting a neighboring cell. Initially, the cell 
morphologically shrinks and loses its cell-cell contacts. At later stages, blebbing of 
the membrane occurs, and finally the cell scatters into multiple small vesicles, or 
apoptotic bodies. These apoptotic bodies are then subjected to phagocytosis, which 
allows for recycling of some of the apoptotic cell content. One of the most common 
features of apoptotic cells is the condensation of the nucleus, followed by its 
fragmentation into smaller pieces. Other organelles are subjected to fragmentation as 
well, i.e. the Golgi apparatus, the ER and the mitochondrion, which leads to the 
release of previously compartmentalized proteins to the cytoplasma. In case of 
mitochondrial lysis, one of the best studied protein in this context is cytochrome C. 
Cytochrome C itself triggers the assembly of the caspase-activating complex and the 
apoptosome, which ultimately leads to caspase activation [15]. 
I.2.2 Caspases
The name caspase is derived from ‘cys-dependent asp-specific protease’. 
Caspases are the main players in executing the apoptotic program. They harbor a 
conserved cysteine side chain and specifically cleave target proteins after an 
aspartate (Asp) residue. Given the specificity of the caspase recognition motif, the 
family of caspases does not merely chop up proteins and foster their degradation, but 
modify proteins at specific residues, which may lead to altered conformation and 
function of these targets. This holds also true for the mode of activation of caspases 
themselves.
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The apoptotic process involves two different kinds of caspases, the initiator 
and the effector caspases. Caspases-8, -9 and -10 are initiator caspases upstream in
the caspase signaling cascade. Whereas caspase-8 and -10 are involved in the 
activation of the extrinsic pathway and can be found in the death-ligand induced 
signaling complex (DISC), caspase-9 is the initiator caspase of the intrinsic pathway 
(see below). Initiator caspases are comprised out of a large and a small subunit 
connected via a linker region that has an unusual length within the catalytic domain. 
Initiator caspases are activated upon dimerization, and, in contrast to effector
caspases, not through cleavage (Fig. I.1A). The main function of initiator caspases is 
the activation of effector caspases by cleavage. Examples for effector capases are 
caspases-3 and -7. They are composed out of a large and a small subunit and exist 
in constitutive dimers, both in the inactive and in the active state (Fig. I.1B). Cleavage 
of the latent form results in the rearrangement within the protein, thereby unblocking 
the catalytic residues and leading to the proper alignment of the substrate binding 
site (Fig. I.1C) [16].
A
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Riedl, S.J. et al., Nat Rev Mol Cell Biol. 2007 May;8(5):405-13 [16].
Figure I.1 Structure and activation of initiator and effector caspases. Panel A. Activation
of initiator caspases through dimerization. Panel B. Schematic overview of the cleavage 
induced activation of effector caspases. Panel C. An activating cleavage of effector caspases 
leads to conformational changes and exposure of the enzymes’s active site.
I.2.3 Pathways of caspase activation
In mammalian cells there are three well known pathways that lead to the 
activation of caspases and subsequent apoptotic cell death: The extrinsic pathway,
the intrinsic pathway and the granzyme b pathway. The extrinsic pathway is induced 
by extracellular ligands that bind to specific cell surface receptors. Typical ligands are 
FasL, tumor necrosis factor-α (TNFα) and TNF-related apoptosis-inducing ligand 
(TRAIL). Binding of the ligand provokes the recruitment of adaptor proteins, such as 
the Fas-associated death domain protein (FADD) which in turn activates caspase-8 
and caspase-10. This complex assembly is also termed Death Inducing Signaling 
Complex (DISC). Caspase-8 and -10 then proteolytically process and activate 
caspase-3 and -7 leading to further caspase activation, and finally apoptotic cell 
death. 
I INTRODUCTION 12
The intrinsic pathway is characterized by various death signals that ultimately 
lead to the release of cytochrome C from the mitochondrial membrane. Typically, this 
is achieved by activation of one or more members of the BH3-only family through cell 
stress or damage. BH3-only proteins act as pathway-specific sensors for a variety of 
stimuli. Importantly, their activation overcomes the inhibitory effect of the anti-
apoptotic B-cell-lymphoma-2 (BCL-2) family members and promotes the assembly of 
BAK-BAX oligomers within mitochondrial outer membranes. These oligomers in turn 
allow the release of cytochrome C from the mitochondrial intermembrane space, 
which then triggers the formation of the apoptosome and subsequent activation of 
caspases. The extrinsic and the intrinsic pathways are interconnected through the
caspase-8-mediated activation of the BH3-only protein BID (BH3-interacting domain 
death agonist) which can promote mitochondrial cytochrome C release followed by 
assembly of the apoptosome (see section I.2.6) (Fig. I.2).
The granzyme b (GrB)-mediated pathway involves the delivery of this 
protease into the target cell through specialized granules that are released from 
cytotoxic T lymphocytes (CTL) or natural killer (NK) cells. CTL and NK granules 
contain numerous granzymes, as well as the pore-forming protein perforin. Perforin 
oligomerizes in the membrane of target cells, thereby permitting the granzymes to 
enter the target cell. [17-19]. Although several different granzymes have been 
described to induce cell death in a perforin-dependent manner [17], the most potent 
and best characterized is GrB. GrB is, like all other known granzymes, a pro-
apoptotic serine protease with the ability, like caspases, to cleave proteins after 
specific Asp residues. These properties enable GrB to directly activate BID and 
caspases-3 and -7 (Fig. I.2) [15]. Although caspase activation is an important 
function of GrB, it has been shown that GrB-mediated apoptosis can occur in the 
absence of active caspases [20, 21]. GrB can directly cleave some nuclear proteins 
such as nuclear matrix antigen and poly(ADP-ribose) polymerase [22], and these 
properties may account for its caspase-independent action. Recently, another 
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caspase-independent pathway has been described, the granzyme A (GrA) pathway. 
Like GrB, GrA enters the target cell through perforin-mediated pores. It has been
demonstrated that GrA activation results in DNA fragmentation in a caspase-
independent manner in cell extracts. The GrA apoptotic pathway is characterized by 
the formation of single-stranded DNA nicks and the appearance of apoptotic 
morphology [23-26]. The pathways leading to caspase activation are summarized in 
Figure I.2.
Adapted from Taylor, R.C. et al., Nat Rev Mol Cell Biol. 2008 Mar;9(3):231-41 [15].
Figure I.2 Three well-known pathways of caspase activation and initiation of apoptosis.
The extrinsic and intrinsic pathways are caspase-dependent, whereas the granzyme B 
activated pathway can be caspase-dependent or -independent.
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I.2.4 Apoptosis versus necrosis
As opposed to apoptosis, cells can also undergo necrosis which is the 
uncontrolled form of cell death. Necrosis is characterized by rapid loss of membrane 
integrity and subsequent swelling and membrane rupture. This in turn results in the 
release of cellular contents into the extracellular space. This release damages 
neighboring cells and in addition it initiates an immune response. Necrotic cells 
trigger inflammation by attracting neutrophils, macrophages and other cells of the 
innate immune system. The molecules causing the attraction of immune cells are 
called danger-associated molecular patterns (DAMPs) or alarmins. They include the 
high mobility group protein B1 (HMGB1), uric acid, certain heat shock proteins, 
single-stranded RNA and genomic DNA. In contrast, apoptotic bodies retain those 
alarmins and additionally facilitate the fast removal of apoptotic cells from the tissue.
Therefore, apoptotic cell death does not initiate an immune response [15].
I.2.5 B-cell lymphoma-2 (BCL-2) family
Proteins of the BCL-2 family are critical regulators of apoptosis and can be 
classified into three subfamilies: the anti-apoptotic BCL-2 family, the pro-apoptotic 
BCL-2 family, and the BH3-only family. All of them contain one to four BCL-2 
homology (BH) domains, and most of them also contain transmembrane domains 
(TM). The anti-apoptotic BCL-2 proteins possess four BH domains and all family 
members inhibit apoptosis by differential binding to BH3-only proteins. This in turn 
prevents BH3-only protein-induced oligomerization of the pro-apoptotic BCL-2 family 
members BAX and/or BAK in mitochondrial outer membranes, which is a required 
event for the induction of the intrinsic apoptotic pathway. The pro-apoptotic BAX-like 
family is characterized by the absence of a BH4 domain. Proteins of this family are 
required for the pore formation in the outer mitochondrial membrane, where they act 
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in form of hetero-oligomers, and are responsible for the subsequent release of 
cytochrome C. The BH3-only protein subfamily currently contains eight family 
members and is a structurally diverse group where the proteins only display 
homology within the BH3 motif. The BH3-only members serve as upstream sentinels 
that respond to specific, proximal death, and survival signals [27]. Some BH3-only 
proteins, such as BID and BIM, interact with all anti-apoptotic BCL-2 protein 
members, whereas others, such as NOXA, interact only with certain family members 
[15]. The regulation of BH3-only proteins is very distinct. For instance, NOXA, PUMA 
and BID are target genes of p53 and are transcriptionally up-regulated by p53. 
Therefore, levels of these proteins are found at increased levels in DNA-damage 
induced apoptosis. BID can be activated by caspase-8 mediated cleavage, resulting 
in tBID mediated BAX/BAK oligomerization. Whereas BAD is regulated by 
phosphorylation, BIM and BMF are freed from their intracellular binding partner 
dynein upon disruption of the cytoskeleton. In addition to that, BIM can be regulated 
by phosphorylation through ERK, resulting in proteasome-mediated degradation of 
BIM [15, 27]. An overview of the BCL-2 family members and their structure is given in 
Fig. I.3.
I INTRODUCTION 16
Taylor, R.C. et al., Nat Rev Mol Cell Biol. 2008 Mar;9(3):231-41 [15].
Figure I.3 Overview of the BCL-2 family members and their structures. There are three 
BCL-2 subfamilies, the anti-apoptotic subfamily, the pro-apoptotic subfamily, and the BH3-
only subfamily.
BCL-2, B-cell lymphoma-2; BCL-XL, BCL2-like 1; BCL-W, BCL2-like 2; MCL1, myeloid cell 
leukemia sequence 1; BCL2A1, BCL2-related protein A1; BCL-B, BCL2-like 10; BAX, BCL-2-
associated X protein; BAK, BCL-2 antagonist/killer-1; BOK, BCL-2-related ovarian killer; BIK, 
BCL-2-interacting killer; HRK, harakiri (also known as death protein -5); BIM, BCL-2-like-11;
BAD, BCL-2 antagonist of cell death; BID, BH3-interacting domain death agonist; PUMA, 
BCL-2 binding component-3; BMF, BCL-2 modifying factor.
I.2.6 The apoptosome
The formation of the apoptosome is an essential step in the promotion of the 
apoptotic cascade as it leads to the activation of caspase-9. The activation process 
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requires caspase-9 to interact with the cofactor apoptotic protease activating factor-1 
(Apaf-1). In the absence of an apoptotic signal Apaf-1 exists in a monomeric form. 
Upon binding to cytochrome C, Apaf-1 recruits caspase-9 in the presence of ATP or 
2’-deoxy ATP (dATP). Apaf-1 consists of three functional regions, an N-terminal 
caspase-recruitment domain (CARD) which binds caspase-9, a nucleotide-binding 
and oligomerization domain (NOD or NB-ARC) which consists of three domains, and 
the C-terminal WD40 repeats (Fig. I.4A) [16, 27]. The WD40 repeats consist of two 
domains and are responsible for the binding of cytochrome C after its release from 
mitochondria. The NB-ARC region is the center for oligomerization and the formation 
of the apoptosome. There is evidence that it also contains an ATPase domain [28]. 
As long as Apaf-1 is in its monomeric form WD40 repeat domains are bound and 
keep it in a locked form. Most likely ATP/dATP is bound to the ATPase domain 
during the locked state of Apaf-1 [29, 30]. Upon an apoptotic signal cytochrome C is 
released from mitochondria and binds to the WD40 repeat region of Apaf-1. dATP is 
hydrolyzed by Apaf-1 which creates a dADP bound conformation of the Apaf-1 
monomer. Now, the lock of the Apaf-1 is released and in a semi-open, but still 
autoinhibited form. In this autoinhibited form the CARD closely interacts with the 
ATPase domain and the winged-helix domain of the NB-ARC region. Therefore, the 
CARD is not accessible and cannot recruit caspase-9, and the blockage of the 
ATPase domain impairs the ability of Apaf-1 to form oligomers. Only a nucleotide 
exchange (dATP for dADP) and interactions with other Apaf-1 monomers or with 
caspase-9 monomers lead to an extended conformation that assembles heptamers 
into the wheel shaped apoptosome (Fig. I.4B). The reason for the ability to form 
oligomers (hexa- or heptamers) is the ATPase domain of Apaf-1. It contains domains 
which are found in a large family of ATPases, the AAA+ family, and without a 
nucleotide exchange Apaf-1 forms the inactive aggregate [16, 29, 30]. Once the 
oligomer is formed, it brings monomers of caspase-9 in close proximity of each other 
and facilitates the formation of caspase-9 dimers, which is the active form of 
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caspase-9 (see I.2.2), thereby triggering the intrinsic apoptotic cascade. The 
importance of Apaf-1 has been demonstrated in Apaf-1 knockout mice, which exhibit 
craniofacial and profound neuronal defects, leading to intrauterine or perinatal death 
of Apaf1-/- mice. This study also demonstrated the strict involvement of Apaf-1 in the 
intrinsic but not extrinsic apoptotic pathway, as FasL-induced apoptosis was largely 
unaffected [31].
A
B
Taylor, R.C. et al., Nat Rev Mol Cell Biol. 2008 Mar;9(3):231-41 [15].
Figure I.4 Structure of Apaf-1 and apoptosome formation. Panel A. The structure of the 
apoptotic protease activating factor-1 (Apaf-1) contains three functional units: the N-terminal 
caspase-recruitment domain (CARD) which is responsible for recruiting caspase-9; a 
nucleotide-binding and oligomerization domain (NOD or NB-ARC) which is responsible for 
(d)ATP (ATP or 2?-deoxy ATP)-dependent oligomerization, and the WD40 region which is 
responsible for binding of cytochrome C. The NB-ARC harbors an ATPase region. It belongs 
to the superfamily of AAA+ ATPases which are generall???????????????????????- and a helical 
domain [32]. In the case of Apaf-1, this region is followed by a winged-helix and a superhelical 
domain. Panel B. In the absence of a signal Apaf-1 exists in a locked autoinhibited form. 
Upon binding of cytochrome C to the WD40 domain and (d)ATP hydrolysis the lock is 
released which leads to a semi-open but still autoinhibited form of Apaf-1. A nucleotide 
exchange is necessary to allow the release of the autoinhibition and the formation of an 
oligomerized, active state.
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I.2.7 Induction of apoptosis by DNA double strand breaks 
DNA double strand breaks (DSBs) may occur in a low frequency within a cell 
and can be repaired. If DSBs occur at a higher frequency or cannot be repaired, the 
cell in which this happens normally becomes apoptotic. However, DSBs may lead to 
genomic rearrangements and to silencing of tumor suppressor genes and/or 
amplification of oncogenes, eventually leading to malignant transformation. Indeed, 
inactivation or loss of DNA repair genes, such as BRCA1, can be found in multiple 
types of cancer. DSBs can be provoked through intrinsic and extrinsic stimuli. 
Common intrinsic stimuli include endogenously generated ROS and mechanical 
stress on the chromosomes, whereas ionizing radiation and chemicals represent 
typical extrinsic stimuli. In the event of a DSB, multiple factors are recruited to the site 
of damage. One key regulating factor upstream of the repair cascade is the kinase 
ATM. This kinase has multiple downstream targets, including BRCA1 and p53 [33, 
34]. Phosphorylation of p53 through ATM leads to its stabilization [35] and activation 
[36]. p53 itself is now able to trigger a pro-apoptotic cascade by up-regulating several 
BH3-only protein upstream of BAX/BAK formation, including PUMA, NOXA and BID 
[37]. Activation of these BH3-only proteins merges then in the formation of BAX/BAK 
complexes and the induction of apoptosis. In addition, BAX itself is downstream 
target of p53. 
The fact that DSB induces apoptosis can be used for cancer treatment. One 
classical chemotherapeutic agent that is widely used to generate DSBs is etoposide. 
Etoposide is a semisynthetic derivate of the naturally occurring mandrake root 
podophyllotoxin. It binds to topoisomerase II, a critical enzyme for DNA unwinding, 
cleavage and ligation. Binding of etoposide particularly inhibits the religation of 
cleaved DNA, thereby increasing the number of DSBs [38]. These DSBs can 
overwhelm the cell and lead to the triggering of death pathways. Interestingly, PKCδ
has been shown to induce the expression of ????????????????? which is also a PKCδ
binding partner, in response to genotoxic stress [39], and aberrant activation of
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?????????????? ??? can trigger the intrinsic apoptotic pathway. The structure of 
etoposide is included in Figure I.5.
Other DSB-inducing agents are listed in Table I.3. Of note, the pro-apoptotic 
effect of DSB-inducing agents appears to be reduced in cells lacking functional p53 
[40].
Figure I.5 Structure of etoposide. Etoposide binds to topoisomerase II. In this manner it 
inhibits religation of cleaved DNA, and thus leading to DNA damage.
DNA double-strand breaking agents Mechanism of DNA double-strand 
break
Cyclophosphamide
Melphalan
Busulfan
Chlorambucil
Mitomycin
Alkylating agents; form interstrand 
and/or intrastrand crosslinks
Cisplatin Forms crosslinks
Bleomycin Cuts DNA strands between GT or GC
Etoposide
Irinotecan
Mitoxantrone
Inhibit the proper functioning of 
enzymes (topoisomerases) needed to 
unwind DNA for replication and 
transcription
Dactinomycin
Inserts into the double helix preventing 
its unwinding
Table I.3 DNA double-strand breaking agents and their mechanisms of action.
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I.3 PKC isozymes
I.3.1 Structure of PKC isozymes
The PKC isozymes belong to the family of lipid-regulated serine-threonine
kinases. The PKC family includes at least 10 isozymes which are classified into three 
groups by their structural and biochemical properties: “classical” calcium-sensitive 
cPKCs α, βΙ, βΙΙ and γ, “novel” nPKCs δ, ε, η and θ which are calcium-independent 
and “atypical” aPKCs ζ and ι/λ [41, 42]. aPKCs do not respond to diacylglycerol 
(DAG) or phorbol esters as opposed to cPKCs and nPKCs. The PKC structure
consists of four well defined conserved domains (C1-C4) located in two regions, the 
N-terminal (or regulatory) and the C-terminal (or catalytical) domain. The N-terminal 
region possesses the motifs involved in the binding of the phospholipid cofactors, 
DAG/phorbol esters and calcium (Ca2+), and it also participates in the associations 
with interacting proteins that control localization. The C1 domain contains a cysteine-
rich motif and serves as the binding site for DAG/phorbol ester. Furthermore, the 
regulatory domain possesses an autoinhibitory pseudosubstrate sequence (PS) 
upstream of the cysteine-rich motif. The PS keeps the protein in its inactive state by 
binding to the catalytic domain of the kinase. The C2 domain contains the recognition 
site for acidic lipids and, in the classical PKC isozymes, the calcium binding site. The 
C3 and C4 domains are located in the C-terminus and form the ATP and substrate 
binding lobes of the kinase, respectively. Upon binding of a C1-ligand, i.e. DAG or 
PMA, to the C1 domains an allosteric conformational change relieves the 
autoinhibition and activates the enzyme. The regulatory and the catalytic domain are 
connected through a highly flexible hinge region which harbors sites for protease 
cleavage. The four conserved (C1-C4) and the five variable (V1-V5) domains of PKC 
isozymes are shown in Table I.3 and Fig. I.6.
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4 conserved domains (C1-C4)
C1 in cPKCs and nPKCs Binding of phorbol esters and DAG
C2 Lipid binding
C3 ATP binding site
C4 Substrate-binding site
Table I.4 PKC isozymes contain four conserved (C1-C4) domains.
Adapted from Kazanietz, M.G., Biochim Biophys Acta. 2005 Dec 30;1754(1-2):296-304 [42]
and Griner, E.M. et al., Nat Rev Cancer. 2007 Apr;7(4):281-94 [41].
Figure I.6 Structure of PKC isozymes. Only cPKCs and nPKCs respond to phorbol esters 
or DAG.
I.3.2 Mechanisms of PKC activation and inactivation
I.3.2.1 PKC maturation
PKC isozymes undergo a process of maturation through a series of 
phosphorylation steps before they become activated. In their C-terminal domain PKC 
isozymes contain an ‘activation-loop site’, a ‘turn motif’, and a ‘hydrophobic motif’. 
For the priming phosphorylation step the enzyme needs to be in an ‘open’ 
conformation. This is the naturally occurring conformation of newly synthesized PKC 
isozymes in which the autoinhibitory PS sequence does not bind to the substrate-
binding cavity. The priming phosphorylation step is initialized by 3-phosphoinositide-
dependent protein kinase-1 (PDK1) which phosphorylates newly synthesized PKCs 
C1A C1B C2
C1A C1B C4
C1
PS
C2 PS
PS
C3
C3
C3
C4
C4
V1 V2 V3 V4 V5
Regulatory region Catalytic (kinase) region
cPKCs (PKCα, βΙ, βΙΙ, γ)
nPKCs (PKCδ, ε, η, θ)
aPKCs (PKCζ, ι/λ)
Phorbol ester/DAG
responsiveness
+
+
-
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at the activation-loop site. Once the phosphorylated C-terminus of PKC is released 
from PDK1, the ‘turn’ and the ‘hydrophobic motif’ are autophosphorylated, and 
conformational changes then free the catalytic domain to bind the autoinhibitory PS 
domain. The mature PKC, now primed for activation by DAG, is released into the 
cytosol and kept in an inactive conformation by intramolecular interactions between 
the N-terminal PS region and the kinase domain (Fig. I.7) [41, 43]. 
I.3.2.2 PKC activation
Stimulation of G-Protein-Coupled Receptors (GPCR) or Tyrosine-Kinase 
Receptors leads to the activation of different isoforms of phospholipase C (PLC) 
which cleave phosphoinositol-4,5-bisphosphate (PIP2) into DAG and inositol-1,4,5-
trisphosphate (IP3). IP3 is released to the cytosol and interacts with a Ca2+ channel 
in the endoplasmatic reticulum (ER), releasing Ca2+ into the cytoplasm. Ca2+ binds to 
the C2 domain of PKCs and translocates it to the plasma membrane. The binding to 
Ca2+ is a low-affinity binding and is not sufficient to activate PKCs. nPKCs are not
pre-targeted to membranes by Ca2+. As a consequence, they translocate slower to 
membranes than cPKCs. Once the PKC has reached the plasma membrane, it
diffuses in the plane of the membrane to bind to its membrane embedded ligand 
DAG (Fig. I.7). Binding of DAG to the C1 domain results in a high-affinity interaction 
of PKC with the membrane. The energy of this interaction leads to a conformational 
change which releases the PS domain from the substrate-binding site. In this 
activated open conformation, mature PKC binds substrates and effects downstream 
signaling [41, 43]. 
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I.3.2.3 PKC inactivation
Biochemical studies revealed that membrane bound, activated PKC is highly 
sensitive to dephosphorylation [44]. Furthermore, it is known that prolonged
activation, i.e. by treatment of cells with phorbol esters, results in increased 
dephosphorylation and turn-over of PKC [45]. Thus, dephosphorylation is a 
frequently occurring event and often involves the protein phosphatase 2A (PP2A) [46, 
47], among others [48]. The dephosphorylated isozyme localizes to the detergent-
insoluble fraction of cells, where it is eventually proteolyzed. Studies suggest that 
PKCα is degraded by the involvement of caveolin-dependent targeting to endosomes 
[49]. Additionally, limited evidence suggests that proteolysis of PKCs may occur 
through an ubiquitin-mediated pathway (Fig.I.7) [50, 51]. However, one efficient way 
by which the cell prevents degradation of dephosphorylated PKC is through its 
association with the heat shock protein HSP70. Association with HSP70 leads to 
stabilization of dephosphorylated PKC and allows for re-phosphorylation, thus 
recycling ‘used’ PKC [52].
Figure I.7 Mechanisms of PKC maturation activation and inactivation. This model 
reflects the mechanisms for cPKCs. nPKCs are calcium-insensitive and therefore translocate 
slower to the plasma membrane. aPKCs do not respond to phorbol ester or DAG and are 
calcium-insensitive.
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I.4 Regulation of apoptotic pathways by PKC isozymes
Although PKC isozymes share a high degree of homology, the cellular roles 
of PKC isozymes are very distinct. Upon binding of a C1 ligand, activation of a 
specific PKC may lead to apoptosis, i.e. as described for the activation of PKCδ in 
LNCaP cells. In contrast, PKCε leads to pro-survival signaling in various cell types. It 
has been shown that PKCε protects cells from apoptosis through activation of the 
anti-apoptotic BCL-2, and conversely, silencing of PKCε induces apoptosis in LNCaP 
cells (Fig. III.9). Over-expression of PKCε in lung cancer cells induces mitogen-
activated protein kinase kinase (MAPKK or MEK) - ERK activation and has been 
shown to up-regulate the pro-survival factors BCL-XL and X-linked inhibitor of 
apoptosis (XIAP). In breast cancer cells PKCε is involved in Akt activation and hence 
pro-survival signaling. Moreover, PKCε fails to protect Akt-depleted cells from 
apoptosis, suggesting that Akt is the major pro-survival pathway activated by PKCε. 
In addition, increased expression of PKCε has been linked to resistance to 
chemotherapeutic agents as shown in non-small-cell lung carcinoma cells [41].
PKCδ on the other hand can trigger pro-apoptotic signaling. Because PKCδ is 
highly susceptible to caspase-3 cleavage at the hinge region, its proteolytic activation 
is a common event during apoptosis. Cleavage in the hinge region results in a 
physical separation of the regulatory domain and catalytic domains. The catalytic 
fragment, which has a molecular weight of 40 kDa, is constitutively active. Some 
chemotherapeutic agents, such as etoposide or cisplatin, or UV radiation are capable 
to induce the generation of the catalytic fragment, and their apoptotic efficacy is 
impaired when PKCδ function or expression is inhibited. Interestingly, PKCδ is 
involved upstream and downstream of caspase-3, as PKCδ cleavage serves as a 
positive feedback signal by relocation of the catalytic fragment to mitochondria and
increasing cytochrome C release (Fig. I.8). 
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Griner, E.M. et al., Nat Rev Cancer, 2007.7(4): p.281-94 [41].
Figure I.8 Pathways of PKCδ-mediated apoptosis. Panel A. PKCδ is subject to caspase-3-
mediated cleavage, i.e. as a consequence of DNA damage, which results in the release of the 
catalytic domain. This in turn facilitates mitochondrial translocation and also exposes a cryptic 
nuclear localization sequence (NLS). Once the catalytic domain of PKCδ translocates into 
these compartments, it may lead to increased release of cytochrome C and phosphorylation 
of nuclear targets, respectively. The latter may be important for the regulation of the cell cycle 
and other nuclear events that occur during apoptosis. Panel B. PKCδ is also capable of 
triggering the extrinsic cascade by modulating the release of death factors, such as TNFα, 
which then leads to the assembly of the DISC and subsequently the induction of apoptosis. 
Cleaved PKCδ can also translocate to the nucleus in response to chemotherapeutic 
agents, which is due to the exposure of a cryptic nuclear localization signal (NLS) 
located at the C-terminus of PKCδ. Impairing the nuclear translocation of PKCδ was 
found to inhibit the apoptotic effect of etoposide. In addition, many other apoptotic 
stimuli can redistribute full length PKCδ to mitochondria, promoting cytochrome C
release, caspase-3 activation, and initiation of the intrinsic apoptotic cycle [53-55]. 
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Oxidative and genotoxic stress can also lead to phosphorylation of full length PKCδ
at a C-terminal tyrosine residue. Importantly, PKCδ-mediated apoptosis could be 
regulated by tyrosine-phosphorylation. This event is likely to be mediated through the 
c-Abl protein tyrosine kinase and promotes nuclear translocation of PKCδ through the 
induction of conformational changes, thereby exposing the otherwise cryptic NLS [56]. 
Previous work from our laboratory demonstrated that activation of PKCδ triggers an
autocrine apoptotic loop ???????? ???? ?????????? ??? ???? and TRAIL [57] in LNCaP 
cells. The integrity of this autocrine loop appears to be critical for the induction of 
apoptosis by phorbol esters [58].
The third DAG/PMA-responsive PKC isoform expressed in LNCaP cells is the 
classical PKCα. In LNCaP cells this PKC isoform facilitates apoptosis through 
activation of PP2A, a phosphatase that dephosphorylates and inactivates Akt. 
Expression of a constitutive active form of Akt (Myr-Akt) prevents PMA-induced 
apoptosis in LNCaP cells. PMA fails to reduce phospho-Akt levels in the presence of 
the PP2A inhibitor okadaic acid. It was also shown that induction of apoptosis by
PMA could be attenuated by specific blockade of PKCα [58]. In addition, activation of 
PKCs by PMA leads to increased levels of phosphorylated p38, and functional 
inhibition of p38 with SB 203580 reduced PMA-induced apoptosis. Interestingly, this 
effect could be ascribed to both PKCα and δ [58]. In summary, the above mentioned 
findings demonstrate once more that the effect of PKC activators on apoptosis is 
both cell type and PKC-isozyme dependent. A summary of the pro-apoptotic 
functions of PKCα and PKCδ in LNCaP cells is shown in Fig. I.9, and the effects of 
PMA in LNCaP cells is summarized in Fig. I.10.
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Adapted from Gonzalez-Guerrico, A.M., et al., J Biochem Mol Biol. 2005
Nov 30;38(6):639-45 [138].
Figure I.9 Signaling pathways of the PKC isoforms involved in apoptosis in LNCaP 
cells. Pro-apoptotic PKCs activate the p38 cascade in LNCaP prostate cancer cells and lead 
to the inactivation of the survival kinase Akt. Whereas both ????? and PKCδ promote
phosphorylation of p38, it is thought that only PKCα triggers the dephosphorylation of Akt by 
activating a phosphatase (PP2A).
Adapted from Gonzalez-Guerrico, A.M., et al., J Biochem Mol Biol. 2005
Nov 30;38(6):639-45 [138].
Figure I.10 Overview of PKC functions. ?????????????????????? ????? respond to phorbol 
esters after its binding to the C1 domain of the PKCs. Each PKC isozyme has distinct roles in 
cellular processes, such as proliferation, differentiation, apoptosis and survival. PKCα and 
PKCδ are pro-apoptotic kinases, whereas PKCε is a pro-survival kinase.
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I.5 Naturally occurring DAG analogs: Phorbol esters and Bryostatins
Phorbol esters are generally known for their tumor promoting activity, and 
naturally occur in Thymelaeaceae and Euphorbiaceae, here especially in Jatropha 
curcas (Fig. I.11). This shrub is widely distributed in many Latin American, Asian and 
African countries. The seed kernels contain up to 60% oil with a fatty acid
composition similar to that of common eatable oils. However, the seeds and seed oil 
are toxic to humans and animals [59], and the toxicity of the seeds of J. curcas has 
been ascribed mainly to the presence of phorbol esters [60, 61].
A
B
Figure I.11 Phorbol ester naturally occur in Euphorbiaceae and Tyhmelaeaceae. Panel 
A. The plant Jatropha curcas L. (Euphorbiaceae) (left panel) bears oil containing seed kernels 
with phorbol ester (right panel). Panel B. Gnidia capitata L.f. (left panel) and Daphne alpine
(right panel) belong to the phorbol ester bearing Thymelaeaceae.
Although a few phorbol ester derivatives are known for their antitumor
activities [62], phorbol esters have been widely used in cancer research because of 
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their high potency as tumor promoters in the mouse skin [63]. It has been in the early 
1980s that PKC isozymes have been identified as the target of the phorbol esters. 
One of the best studied phorbol ester in this regard is phorbol 12-myristate 13-
acetate (PMA), also known as tetradecanoyl phorbol acetate (TPA) which has been 
used for decades as a PKC activator. It mimics the action of DAG and binds to the 
C1 domain of PKCs with high affinity. Of note, PMA has higher potency and stability 
than DAG itself which makes it one of the most valuable pharmacological tools to 
study multistage carcinogenesis in vivo. In addition to its tumor promoting activity, 
PMA leads to numerous cellular responses, including mitogenesis, cell growth arrest, 
survival, apoptosis, differentiation, and transformation, depending on the cell type.
Other natural products mimicking DAG activity are the daphnane derivatives,
mezerein and thymeleatoxin, ingenol esters, aplysiatoxins, teleocidines such as 
indolactam V (ILV), and bryostatins [64, 65].
Bryostatin 1 is of particular interest, since it has been described to have 
effects on PKCs that only partially recapitulate the effects provoked by PMA. 
Bryostatins are macrocyclic lactones which were first isolated in the late 1960s by 
George Pettit and co-workers from extracts of a species of the bryozoan Bugula 
neritina. Currently, there are 20 known natural bryostatins differing mainly in the 
nature of the substituents at positions C7 and C20 [66]. Importantly, the bryostatins 
have been shown to competitively inhibit the binding of phorbol esters and 
endogenous diacylglycerol to PKCs at low nanomolar to picomolar concentrations 
and to stimulate comparable kinase activity in vitro by binding to the C1 domains of
cPKCs and nPKCs [66, 67]. However, while bryostatins mimic several phorbol ester 
responses, they display unusual pharmacological properties as they fail to induce 
phorbol ester-like responses in many cellular models. More interestingly, bryostatins 
functionally antagonize phorbol ester responses that they themselves are unable to 
elicit, including tumor promotion [68, 69].
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Figure I.12 Structures of PKC activators. Diacylglycerol (DAG), phorbol 12 myristate 13-
acetate (PMA), and bryostatin 1 activate PKC isozymes by binding to their C1 domain.
Preliminary biological screening had revealed bryostatins to be powerful 
antitumor agents in vitro, and efforts were made to identify the structure of bryostatin 
1, which was achieved in 1982, also by George Pettit and co-workers (Fig I.12) [70]. 
The in vitro antitumoral effects of bryostatin 1 were later confirmed in vivo in a 
number of established murine tumor models [71, 72]. In addition, it was found that 
the bryostatins exhibit potent anti-tumor activity against a broad range of human 
cancer cell lines and provide significant in vivo life extensions in murine xenograft
tumor models [66]. Currently, bryostatin 1 is evaluated alone and in combination with 
other chemotherapeutic agents in over 25 phase I and II human clinical trials for 
melanoma, myeloma, chronic lymphocytic leukemia (CLL), AIDS- related lymphoma, 
non-Hodgkin’s lymphoma, colorectal, renal, prostate, head and neck, cervix, ovarian, 
Diacylglycerol
Bryostatin 1 Phorbol 12-myristate 13-acetate
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breast, peritoneal, stomach, esophagus, anus, prostate, and non-small cell lung 
cancer [73-77]. Results of several clinical trials have indicated that bryostatin 1 is well 
tolerated with no acute toxicities. The dose-limiting toxicity in all cases has been 
myalgia (muscle pain) which is relieved upon cessation of treatment. Efficacy has 
been observed in these clinical studies including several partial and complete 
responses for advanced, refractory forms of cancer [66].
I.6 Aims of the study
As outlined above, PKC isozymes play a fundamental role in the induction of 
apoptosis in LNCaP cells. In particular, PKCδ has been suggested to be of major 
importance for the induction of apoptosis in this cell line. PKCs can be influenced by 
multiple stimuli, both endogenous (DAG) and exogenous (PMA and bryostatin 1). 
However, PMA and bryostatin 1 only partially provoke identical responses upon 
binding to the C1 domain of PKCs, and have opposing effects with regard to the 
responses they do not share. Because bryostatin 1 is in clinical trials for various 
cancers, but not prostate cancer, the following question should be investigated in this 
study:
Specific Aim 1: To assess the effect of bryostatin 1 on LNCaP prostate cancer cells 
and whether it affects PMA-induced apoptosis in this cell line.
In addition, different C1 domain containing PKC isozymes have different 
targets, which is reflected in isoform-specific responses of a cell to PMA. 
Phosphorylation of target proteins may ultimately lead to changes in gene expression, 
i.e. through stabilization/destabilization or subcellular translocation of a 
phosphorylated signaling molecule or transcription factor. However, it has not been 
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systematically addressed so far whether and to which extend PKC activation by PMA 
and subsequent apoptosis in LNCaP cells involves transcriptional regulation in an 
isoform-dependent manner. To address these issues, the specific aim 2 is as follows:
Specific Aim 2: To elucidate the impact of PKC isozyme activation on transcriptional 
regulation in LNCaP cells in the context of PMA-induced apoptosis. 
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II MATERIALS AND METHODS
II.1 Compounds for cell culture treatment
Bryostatin 1 was purchased from EMD (Gibbstown, NJ, USA). A stock of 100 
µM was prepared in DMSO and stored at -20°C. Phorbol 12-myristate 13-acetate 
(PMA) was obtained from LC Laboratories (Woburn, MA, USA). A 1 mM stock 
prepared in 100 % ethanol was stored at -80°C. Etoposide was purchased from EMD 
(San Diego, CA, USA) and dissolved in DMSO at a concentration of 100 µM. 
Cycloheximide was purchased from Sigma (St. Louis, MO, USA) and dissolved in 
100% ethanol to concentration of 50 mM. TNFα was purchased from Peprotech 
(Rocky Hill, NJ, USA). 
II.2 Cell Culture
II.2.1 Cultivation of cells
The prostate cancer cell line LNCaP, clone FGC (CRL-1740), was cultured in 
RPMI 1640 medium supplemented with inactivated 10% FBS, penicillin (100 units/ml)
and ???????????????????????) (complete RPMI 1640) at 37°C in a humidified 5% CO2
atmosphere. Cells were grown in an adherent monolayer in tissue culture dishes on 
an area of 60 cm2 and were passaged twice a week. Cells were washed with pre-
warmed (37°C) RPMI 1640 medium to avoid detachement of the cells. One ml of 
0.05% Trypsin/EDTA was added to a p100 plate and incubated for 3 to 5 min at 37°C 
in a humidified 5% CO2 atmosphere. After cell detachment, 11 ml of complete RPMI 
1640 medium were added to inactivate the Trypsin/EDTA solution. Cells were 
thoroughly resuspended and either passaged in a ratio of 1:3 or 1:4 into 3 or 4 p100 
plates, respectively. To avoid loss of androgen-dependency the cell density never 
exceeded 70-80%, and cells were only used from passage 2 to 8 for all experiments.
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II.2.2 Materials
Product Company
LNCaP clone FGC (CRL-1740)
Prostate Carcinoma; human
American Type Culture Collection, 
Manassas, VA, USA
RPMI 1640 medium American Type Culture Collection
Fetal bovine serum (FBS) Hyclone, Logan, UT, USA
Penicillin/Streptomycin solution Invitrogen, Carlsbad, CA, USA
0.05% Trypsin-EDTA Invitrogen
Dimethylsulfoxide (DMSO)
Thermo Fisher Scientific, Rochester, NY, 
USA
Tissue culture dishes (22.1 cm2, 60.1 cm2) TPP, Trasadingen, Switzerland
BD Falcon™ 6- and 12-well Multiwell Plates BD Biosciences, San Jose, CA, USA
BD Falcon™ Serological pipets BD Biosciences
15 and 50 ml conical tubes
GeneMate/ISC BioExpress, Kaysville, UT, 
USA
Corning® 2ml External Threaded 
Polypropylene Cryogenic Vial
Corning Incorporated Life Sciences, Lowell, 
MA, USA
13 mm syringe filter (0.45 µm pore size) Thermo Fisher Scientific
5100 Cryo 1°C Freezing Container, "Mr. 
Frosty"
Nalgene Labware, Thermo Fisher Scientific
Jouan CR 312 centrifuge Jouan, now Thermo Fisher Scientific
US AutoFlow NU-4750 incubator Nuaire, Plymouth, MN, USA
Table II.1 Materials used for cell culture.
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II.2.3 Freezing and thawing of LNCaP cells
Freezing medium with 5% of DMSO
DMSO 2.5 ml
Complete RPMI 1640 47.5 ml
Table II.2 Composition of freezing medium
The purchased LNCaP cells were warmed up at 37°C by holding the cryovial 
into a pre-warmed water bath (37°C) until they started thawing (30-60 sec). Cells 
were completely defrosted by gently dissolving in 30 ml pre-warmed medium.
Subsequently, cells were centrifuged (1,000 rpm, 5 min) to remove DMSO and cell
debris. After resuspending the cell pellet in 10 ml fresh medium, cells were plated
and left to grow (considered as passage 1) in a 100 mm dish. After reaching a 
confluency of 70-80% cells were passaged in a 1:3 ratio (passage 2). Cells were 
again 70-80% confluent before freezing or using them for experiments (passage 3). 
To freeze cells a special freezing medium was prepared (Table II.2: Freezing 
medium for LNCaP cells) containing DMSO to avoid cell rupture. Complete RPMI 
1640 medium was removed from the cells. Cells were washed once with 7 ml of 
complete RPMI 1640, and 1 ml of 0.05 % Trypsin/EDTA was added to the cells and 
incubated for 3 to 5 min at 37°C in a humidified 5% CO2 atmosphere. After 
detachment, cells were resuspended thoroughly in 11 ml of complete RPMI 1640, 
transferred into a 15 ml conical tube and centrifuged (1000 rpm, 5 min, 4°C). The 
supernatant was removed and the cell pellet was resuspended in 2 ml (1:2) of ice-
cold freezing medium for LNCaP cells. One ml of the cell suspension was transferred 
into each cryovial and transferred into a pre-cooled (4°C) freezing container. This 
special freezing container provides a cooling rate of -1°C/minute. The freezing 
container was then transferred into the -80°C freezer. Two days later the cryovials 
were transferred into liquid nitrogen for long-term storage.
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II.2.4 Inactivation of fetal bovine serum (FBS)
Frozen fetal bovine serum was thawed overnight at 4°C. Thawed serum was 
left at room temperature for 2 h. Afterwards, the bottle of serum was heated at 56°C 
for 30 min in a water bath containing enough water to immerse the bottle to just 
above the level of the serum. The bottle with serum was swirled every 5 to 10 min to 
assure equal temperature throughout the entire bottle. After 30 min, serum was 
cooled down on ice immediately, aliquoted in 50 ml aliquots, and stored at -20°C.
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II.3 Apoptosis assay
II.3.1 Materials
Product Company
4´,6-Diamidine-2´-phenylindole 
dihydrochloride (DAPI)
Roche Applied Science, Indianapolis, IN, 
USA
Phosphate Buffered Saline (PBS) 7.4 
(1X)
Invitrogen
Dimethylsulfoxide (DMSO) Thermo Fisher Scientific
0.05% Trypsin/EDTA Invitrogen
15 ml conical tube GeneMate/ISC BioExpress
Fluoromount-GTM SouthernBiotech, Birmingham, AL, USA
Corning® 75 x 25mm Microscope 
Slides, Frosted OneSide, One End
Corning Incorporated Life Sciences,
Corning® 22 x 50mm Rectangular #1 
Cover Glass
Corning Incorporated Life Sciences
Nikon Eclipse Microscope TE 2000-U Nikon Instrument Inc., Melville, NY, USA
Microscope Camera: Dual-View Optical 
Insights OJ-05-EM
Nikon Instruments Inc.
Dual-View wavelength splitter with an 
OI-05-Ex excitation filter (436 ± 20 nm) 
and OI-05-Em emission filter (480 ± 30 
nm)
Optical Insights, Tucson, AZ, USA
Microscope Software: Northern Eclipse
Empix Imaging Inc., Cheektowaga, NY, 
USA
Table II.3 Materials for apoptosis assay.
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II.3.2 DAPI staining
DAPI was reconstituted in distilled H2O to obtain a stock solution at a
concentration of 1 mg/ml, aliquoted and stored in the dark at -20°C. A working 
solution of 1 µg/ml DAPI in PBS was prepared prior to use.
2 x 105 cells were seeded into a 6-well plate and cultured for 2 days. Cells
were then treated with either vehicle (ethanol and/or DMSO), PMA 100 nM and/or 
bryostatin at various concentrations (1, 10 or 100 nM). Forty-eight h after treatment 
the medium containing detached apoptotic cells was transferred into a 15 ml conical 
tube. To wash the remaining attached cells 2 ml of PBS/well were added, removed 
and transferred to the same tube as the detached cells. The attached cells were 
trypsinized with 0.5 ml of 0.05% Trypsin-EDTA/well at 37°C in a humidified 5% CO2
atmosphere. Two ml of PBS were added to the trypsinized cells and combined with 
the already collected cells of one sample in the 15 ml conical tube. The tube was 
then centrifuged for 5 min at 1,000 rpm at 4°C. The supernatant was removed and 
the cell pellet carefully resuspended in 200 µl of PBS. One hundred µl of the cell 
suspension were mounted on glass slides and fixed in 70% pre-cooled (-20°C) 
ethanol for 20 min at -20°C. Morphological changes in chromatin structure were 
assessed after staining with DAPI/PBS solution for 20 min in the dark at 4°C [11, 58]. 
Apoptosis was characterized by chromatin condensation and fragmentation when 
examined by fluorescence microscopy (Fig. II.1). The percentage of apoptosis was 
determined by counting a total of 300 cells per preparation. In previous studies our 
laboratory found that the results with this method match those obtained by flow 
cytometry and correlate with DNA laddering analysis [14, 57].
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Figure II.1 Micrographs of LNCaP cells stained with DAPI. LNCaP cells treated with 100 
nM PMA for 1 h undergo apoptosis as indicated with an arrow (right panel).
II.3.3 Generation of Conditioned medium (CM)
1.5 x 106 LNCaP cells were seeded in a tissue culture dish (100 mm) 
(secretor cells) and 2 x 105 cells in a 6-well plate (receptor cells). Two days later 
secretor cells were washed and medium prepared with agent, i.e. PMA or bryostatin 
1 was added to the cells for 60 min. Then, cells were washed twice with RPMI 1640 
medium to remove residual compounds and 7 ml of medium were added to the cells. 
Receptor cells were washed with RPMI-1640 and 2 ml of fresh medium were added.
After 24 h, the conditioned medium generated by the secretor cells was collected in
15 ml conical tubes or in 1.5 ml eppendorf tubes and centrifuged at 1,000 rpm for 5 
min at 4°C or 4,000 rpm for 5 min at 4°C, respectively. The supernatant was filtered
through a 13-mm syringe filter (0.45 µm pore size) and the medium of the receptor 
cells was replaced with 1 ml CM. LNCaP cells were ~70% confluent at the time they 
were treated with CM. Receptor cells were collected 24 h later for evaluation of 
apoptosis as described in section 3.2. For experiments using a TNFα rescue 
approach, TNFα was added to CM to achieve final concentrations of 0.1, 1.0 and 10 
ng/ml.
PMAControl
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II.3.4 Treatment of LNCaP cells with etoposide
LNCaP cells were serum starved (RPMI 1640 without FBS) and 48 h later 
treated with 400 µM etoposide. Cells were harvested (see section 8.1) and RNA was 
isolated 5 h after treatment with the RNeasy Mini Kit (Qiagen Inc., Valencia, CA, USA)
as described in section II.10.1 To assess the percentage of apoptosis cells were 
collected and stained with DAPI 48 h after treatment with etoposide.
II.3.5 Treatment of LNCaP cells with cycloheximide
Cycloheximide, an antibiotic produced by Streptomyces griseus, inhibits 
translation in eukaryotes by interfering with the binding and transfer of tRNA to and 
from the ribosome during protein synthesis [78]. 2 x 105 LNCaP cells were seeded in
6-well plates. Two days later cells were treated with 50 µM cycloheximide for 40 min,
and then 100 nM PMA was added for 1 h. After extensive washing with medium, 50 
µM cycloheximide were added again. After 24 h, cells were stained with DAPI and 
the percentage of apoptosis was assessed as described in section II.3.2.
II.4 Transfection
Transfection is the process of introducing nucleic acids into eukaryotic cells 
by nonviral methods. The negatively charged phosphate backbones of DNA or RNA 
are coated by chemicals like calcium phosphate, DEAE-dextran, or cationic lipid-
based reagents. This leads to neutralization or a positive charge of the nucleic acids 
which makes it easier for the DNA/RNA-transfection-reagent-complex to cross the 
membrane. Especially lipids will fuse more easily with the lipid bilayer. By contrast, 
physical transfection methods like microinjection or electroporation create little pores 
in the plasma membrane and the DNA is introduced directly into the cell [79].
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II.4.1 Transfection by electroporation
Product Company
Amaxa® Nucleofector® Device Lonza, Walkersville, MD, USA
Nucleofector® Kit R Lonza
Table II.4 Transfection devices.
Plasmid DNA or siRNA were introduced into LNCaP cells by electroporation 
using the Amaxa Nucleofector®. Here, an electrical pulse perturbs the cell membrane 
and forms transient pores that allow the passage of nucleic acids into the cell [80].
LNCaP cells were cultured 2-3 days before the nucleofection and cultured as 
described above until they reached a confluency of 70-80%. The Nucleofector®
solution R was prepared as described in Table II.5. One to five µg of DNA were 
mixed with 100 µl of Nucleofector® solution R. Cells were trypsinized and counted. 
For each transfection 2 x 106 cells were transferred into a 15 ml conical tube and
centrifuged (1,000 rpm, 4°C, 5 min). The supernatant was discarded and the cell 
pellet resuspended in 100 µl of DNA containing Nucleofector® solution R (room 
temperature). One nucleofection® sample contained: 
2x106 cells
1-5 µg plasmid DNA
100 µl Nucleofector® solution R
The nucleofection sample was transferred into an Amaxa certified cuvette. 
For LNCaP cells the Nucleofector® program T-009 was used. To avoid damage of 
the cells the sample was removed from the cuvette immediately after the program 
had finished. Five hundred µl of pre-warmed complete RPMI 1640 medium were
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added to the cuvette. The sample was transferred to a 15 ml conical tube containing 
pre-warmed complete RPMI 1640 medium using the plastic pipette provided in the 
Nucleofector® Kit R. The appropriate volume to obtain a cell number of 3x105/ 6-well 
was transferred into a 6-well plate.
The transfected cells were incubated at 37°C in a humidified 5% CO2
atmosphere for 24 to 48 h depending on the plasmid and experiment.
Nucleofector® solution R (4°C)
Nucleofector® solution 2.25 ml
Supplement I 0.5 ml
Table II.5 Composition of Nucleofector® solution R.
II.5 Immunofluorescence and confocal microscopy
Product Company
Fisherbrand Microscope Cover Glass Thermo Fisher Scientific
Anti-Myc Tag (rabbit polyclonal IgG) Upstate (Millipore), Billerica, MA, USA
Alexa-Fluor 488 goat anti-rabbit IgG Invitrogen
Table II.6 Additional materials for immunofluorescence and confocal microscopy.
For localization studies of GFP-fused PKCs, 2 x 106 LNCaP cells were 
transfected with 2 µg of pEGFP-N1-PKCα, pEGFP-N1-PKCδ or pEGFP-N1-PKCε [81, 
82] as described in section II.4.1. 105 cells were plated on sterile round cover-slides 
in 12-well plates. After 48 h cells were stimulated for 20 min with 100 nM PMA, 100 
nM bryostatin 1, or 100 nM PMA/100 nM bryostatin 1. Cells were then washed with 
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PBS and fixed with pre-cooled methanol (-20 oC) for 10 min at -20oC. Samples were 
stained with DAPI (1 µg/ml) for 10 min at 4oC, mounted on a glass slide, and 
visualized with a Zeiss LSM510 META NLO laser scanning confocal microscope.
In a different set of experiments, cells were transfected with plasmids 
encoding myc-tagged PKCs generated (see section II.8 for details). Twenty-four h 
post-transfection, cells of one 12-well were fixed in 1 ml of pre-cooled methanol (-20
oC) for 10 min at -20°C. After blocking with 500 µl of 5% BSA/PBS for 1 h at room 
temperature cells were incubated with a rabbit polyclonal anti-myc antibody (Millipore) 
for 1 h at room temperature in 5% BSA/PBS (1:500). Following wash steps (3 x 5 min 
PBS on an orbital shaker), samples were probed with a secondary Alexa Fluor 488 
coupled anti-rabbit antibody (Invitrogen) for 1 h at room temperature (1:2000). Finally, 
slides were washed, counterstained with DAPI (1 µg/ml) for 10 min at 4°C, and 
visualized by confocal microscopy.
II.6 Measurement of cytokines in the CM
Enzyme-linked Immunosorbent Assay (ELISA) is a highly sensitive technique 
for detecting and measuring antigens in a solution. The solution is run over a surface 
to which immobilized antibodies (capture antibodies) specific to the antigen have 
been attached. If the antigen is present it will bind to the immobilized antibody layer. 
Next, the enzyme linked antibodies (detection antibodies) are added and will bind 
specifically to a different epitope of the same antigen. The enzyme converts a 
chemical into a color, fluorescent, or electrochemical signal to detect the presence of 
the antigen. The absorbance, fluorescence, or electrochemical signal is proportional 
to the concentration of the antigen.
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II.6.1 ELISA for humhan TNFα (Sandwich ELISA)
Product Company
Human TNFα-ELISA Development Kit Peprotech, Rocky Hill, NJ, USA
ELISA microplates Nunc MaxiSorb, Rochester, NY, USA
Tween-20 Sigma, St.Louis, MO, USA
BSA Sigma
ABTS Liquid Substrate Solution Sigma
Phosphate Buffered Saline (PBS) pH 7.4 Invitrogen
Table II.7 Materials for ELISA.
ELISA components
Capture antibody Antigen-affinity purified rabbit anti-hTNFα
Detection antibody Biotinylated antigen-affinity purified rabbit anti-hTNFα
Human TNFα standard Recombinant hTNFα
Avidin-HRP conjugate
Table II.8 Components of ELISA. The components were reconstituted as instructed by the 
manufacturer, aliquoted, and stored at -20°C.
To determine TNFα levels in CM, 2 x 105 cells were plated in a 6-well plate 
and treated 48 h later cells with bryostatin 1 +/- PMA for 60 min. After 60 min cells 
were washed and 1 ml of fresh RPMI 1640 medium was added for 24 h. The CM was 
collected in microcentrifuge tubes and centrifuged at 4,000 rpm (4°C, 5 min) and 
either used immediately for ELISA or stored at -80°C. 
The 96-well ELISA plate was prepared by adding 100 µl of capture antibody 
(1 µg/ml in PBS) to each well. The plate was sealed with parafilm and incubated on 
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an orbital shaker overnight at 4°C. The following day the plate was washed 4 times
with 300 µl of wash buffer (0.05% Tween-20/PBS). After the last wash the plate was 
inverted to remove residual buffer and blotted on a paper towel. To minimize any 
non-specific binding sites, plates were incubated for 1 h at room temperature with
300 µl of blocking buffer. 
Different dilutions of the recombinant hTNFα standard were added 
immediately to each well in triplicate and incubated on an orbital shaker at room 
temperature for 2 h to allow for binding of TNFα to the capture antibody. Afterwards, 
the plate was washed as described above, 100 µl of the biotinylated detection 
antibody (0.5 µg/ml) were added, and incubated at room temperature for 2 h. Once 
more the ELISA plate was washed and incubated with 100 µl of avidin-HRP 
conjugate (1:2000 in diluent) for 30 min at room temperature. The plate was washed 
again. One hundred µl of a room temperature aliquot of ABTS liquid substrate 
solution was added to each well. After 20 min the color development was measured 
with the Emax precision microplate reader at 405 nm. The data analysis was 
conducted with the software SoftMax® Pro (both Molecular Devices, Sunnyvale, CA, 
USA).
Solutions for ELISA
PBS
Wash buffer 0.05% Tween-20 in PBS
Block buffer 1% BSA in PBS
Diluent 0.05% Tween-20, 0.1% BSA in PBS
Table II.9 Solutions for ELISA experiment.
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II.6.2 RayBio® Human Cytokine Antibody Array 
To detect different cytokines simultaneously in CM the RayBio® Human 
Cytokine Array 5 (4) was used (RayBiotech, Inc., Norcross, GA, USA).
Membranes were blocked for 30 min with blocking buffer provided by the 
manufacturer. Afterwards, membranes were washed with provided wash buffers and 
subsequently incubated with 1 ml of CM generated from cells treated with either 10 
nM bryostatin 1 or 100 nM PMA, alone or in combination or vehicle for 2 h. The 
membranes were washed again and each membrane was incubated with 1 ml of a 
solution with diluted biotin-conjugated antibodies for 90 min. After subsequent 
washing, the membranes were incubated for 2 h at room temperature with 2 ml of 
HRP-conjugated streptavidin. Finally, membranes were incubated for 2 min with the 
provided detection buffers (Fig. II.2). The signal was detected by enhanced 
chemiluminescence using the LAS-3000 imaging system and Multi Gauge software 
(both Fujifilm, Edison, NJ, USA). Exposure time was 40 sec. Every step of the 
protocol was performed at room temperature.
Figure II.2 RayBio® Human Cytokine Antibody Array Protocol (Ray Biotech, Inc.).
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II.7 Western Blot Analysis
II.7.1 Isolation of proteins
Lysis buffer (4°C)
Final concentration Volume
HEPES 1 M 25 mM 2.5 ml
NaCl 5 M 150 mM 3.0 ml
NP40 10% 1% 10.0 ml
Sodium deoxycholate 10% 0.25% 2.5 ml
Glycerol 10% 10 ml
MgCl2 1 M 10 mM 1 ml
EDTA 0.5 M 1 mM 0.2 ml
dH2O to 100 ml
Table II.10 Composition of protein lysis buffer. Protease inhibitor (PI) (Sigma, St. Louis, 
MO) was added to the lysis buffer 1:500 right before use.
4x Sample buffer
Final concentration Volume
Tris HCl 0.5M, pH 6.8 250mM 5.0 ml
Glycerol 30% 3.0 ml
SDS 8% 0.8 g
-> 60°C to dissolve SDS
Bromophenol blue 0.1% 0.001% 100 µl
dH2O to 10.0 ml
Table II.11 Composition of 4x Sample buffer. 2% β-mercaptoethanol were added before 
use.
2 x 105 LNCaP cells were seeded in 6-well plates. After treatment cells were 
carefully washed with 1 ml of PBS. PBS was at room temperature to avoid 
detachement of the cells. The plates were then transferred on ice and 100 µl of 
complete lysis buffer were added to each well. Cells were scraped off the well with a 
cell scraper and transferred to a 1.5 ml microcentrifuge tube, placed on ice and 
II MATERIALS AND METHODS 49
incubated for 20 min. Subsequently, cells were centrifuged at 13,000 rpm (4°C for 10 
min). The supernatant was transferred to new tubes and the protein concentration
was determined by the Bradford method as described in section 7.2. Lysates were
stored at -80°C or prepared for Western Blot as follows. Proteins were kept on ice, 
and 20 µg of protein were pipeted into a new tube. All samples were adjusted with 
protein lysis buffer containing protease inhibitor (PI) (Sigma) to the same volume. 
Subsequently, the appropriate volume of 4X sample buffer was added to achieve a 
final concentration of 1X sample buffer. The samples were then incubated in a 95°C 
water bath, and 20 µg of protein were subjected to SDS-PAGE.
II.7.2 Protein Quantification
The protein concentration was measured by the Bradford method [83]. To 
obtain a standard curve, Bovine Serum Albumin Standard (BSA, Pierce 
Biotechnology, Inc., Rockford, IL, USA) was used from 0 to 8 µg/ml. For protein 
quantification the Bio-Rad Protein Assay (Bio-Rad Laboratories, Hercules, CA, USA) 
solution was diluted 1:5 in dH2O. Protein concentrations were assessed in standard 
disposable polystyrene cuvettes and measured in a SmartSpec Plus 
Spectrophotometer (Bio-Rad Laboratories) at 595 nm.
II.7.3 SDS-PAGE 
Protein samples are separated by discontinuous denaturizing SDS-PAGE 
according to Laemmli [84]. The discontinuous electrophoresis system used here 
consists of two layers: the stacking gel, where the proteins are concentrated and the 
separating gel, where the proteins are separated according to the molecular size. 
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The compositions of the gels and buffers used for SDS-PAGE are shown in Tables 
II.12, II.13, II.14, II.15, and II.16.
Separating gel (10%)
dH2O 4 ml
1.5 M Tris HCl, pH 8.8 2.5 ml
10% SDS 100 µl
30% Acrylamide/Bis Solution 3.3 ml
APS 10% 100 µl
TEMED 4 µl
Table II.12 Working solution for separating gel 10%.
Stacking gel
dH2O 6 ml
0.5 M Tris HCl, pH 8.8 2.5 ml
10% SDS 100 µl
30% Acrylamide/Bis Solution 1.3 ml
APS 10% 50 µl
TEMED 4 µl
Table II.13 Working solution for stacking gel 3.9%.
Electrophoresis buffer (1X)
Tris-Glycine (10X) 100 ml
SDS 10% 10 ml
dH2O to 1 l
Table II.14 Working solution for electrophoresis
Tris-Glycine (10X)
Tris Base 30 g
Glycine 144 g
dH2O to 1 l
Table II.15 Tris-glycine stock solution (10X).
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Proteins Acrylamide concentration
PKCα 7.5 or 10%
PKCδ 7.5 or 10%
PKCε 7.5 or 10%
Akt 10%
phospho-Akt (Ser473) 10%
P44/42 MAP Kinase 10%
phospho-p44/42 MAP Kinase (Thr202/Tyr204) 10%
SAPK/JNK 10%
phospho-SAPK/JNK (Thr183/Tyr185) 10%
P38 MAP Kinase 10%
phospho-p38 MAP Kinase (Thr180/Tyr182) 10%
p21Cip1 12%
Table II.16 Acrylamide concentrations in the separating gel. The concentration varies 
according to the analyzed protein
To determine the molecular weight of the proteins, samples were compared to
a prestained low range molecular weight marker (SDS-PAGE Standard, Bio-Rad 
Laboratories, Hercules, CA, USA). Electrophoresis was performed using a vertical 
Mini-PROTEAN Tetra Cell (Bio-Rad Laboratories, Hercules, CA, USA) connected to 
a power supply (Bio-Rad Laboratories, Hercules, CA, USA).
Electrophoresis was run at 60 V until the proteins started separating in the 
separation gel. When the marker dye had entered the separation gel the current was 
set at 110 V until completion of the electrophoretic separation.
II.7.4 Western Blotting and detection
After the electrophoresis, proteins were transferred from the gel onto a 
polyvinylidenflouride (PVDF) blotting membrane. The membrane was activated by 
soaking in methanol for 30 sec. Subsequently, the activated membrane was soaked 
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in 1X transfer buffer together with the blotting pads, Whatman paper, and the gel. 
These transfer supplies were assembled in transfer sandwiches in the order 
described below (Table II.17 and II.18).
Sandwich holder anode side
wetted pad
Whatman paper
Membrane
Gel
Whatman paper
wetted pad
Sandwich holder cathode side
Table II.17 Setup of transfer sandwich.
Transfer buffer 1x (4°C)
Tris-Glycine (10x) 100 ml
Methanol 200 ml
dH2O to 1 l
Table II.18 Components of transfer buffer (1X).
Transfer sandwíches were transferred into the Western blot tank (Bio-Rad 
Laboratories) containing Transfer buffer 1X. The transfer was conducted at 100 V for 
1 h at 4°C or at 30 V overnight at 4°C.
Afterwards, PVDF membranes were stained with Ponceau S (Sigma) for 5 
sec to verify the efficieny of the transfer and equal loading, washed with dH2O and 
blocked with 5% skim milk/TBS-T 0.1% for 1 h at room temperature. Membranes 
were shortly washed 3 times for 5 min with TBS-T 0.1% and incubated with primary 
antibody at 4°C over night (see Table II.20 for primary antibodies and dilutions). All 
primary antibodies were diluted in 5% BSA/TBS-T 0.1%.
The following day, membranes were washed 3 times for 5 min with 5% TBS-T 
0.1% and incubated for 1 h with either anti-mouse or anti-rabbit secondary antibodies 
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conjugated to horseradish peroxidase (1:5000 in 5% skim milk/TBS-T 0.1%, Bio-Rad)
(see Table II.21 for secondary antibodies and dilutions). Subsequently, the 
membrane was washed 3 times for 10 min with TBS-T 0.1%. Bands were visualized 
by enhanced chemiluminescence using the LAS-3000 imaging system and Multi 
Gauge software (both Fujifilm, Edison, NJ).
Ponceau S solution
Ponceau S 0.2% 0.2 g
glacial acetic acid 3% 3 g
dH20 to 100 ml
Table II.19 Composition of Ponceau S solution.
primary antibody isotype dilution Company
PKCα, clone M4 mouse IgG1 1:1000 Upstate (Millipore),
PKCδ rabbit IgG 1:1000 Cell Signaling Technology;
Danvers, MA, USA
PKCε rabbit IgG 1:500 Santa Cruz Biotechnology,
Santa Cruz, CA, USA
Akt rabbit IgG 1:1000 Cell Signaling Technology
phospho-Akt (Ser473) rabbit IgG 1:1000 Cell Signaling Technology
p44/42 MAP Kinase rabbit IgG 1:1000 Cell Signaling Technology
phospho-p44/42 MAP 
Kinase (Thr202/Tyr204)
rabbit IgG 1:1000
Cell Signaling Technology
SAPK/JNK rabbit IgG 1:1000 Cell Signaling Technology
phospho-SAPK/JNK 
(Thr183/Tyr185)
rabbit IgG 1:1000
Cell Signaling Technology
p38 MAP Kinase rabbit IgG 1:1000 Cell Signaling Technology
phospho-p38 MAP Kinase 
(Thr180/Tyr182)
rabbit IgG 1:1000
Cell Signaling Technology
p21Cip1 mouse IgG2a 1:1000 Cell Signaling Technology
β-actin, clone AC-15 mouse IgG1 1:40000 Sigma, St. Louis, MO, USA
vinculin, clone hVIN-1 mouse IgG1 1:5000 Sigma, St. Louis, MO, USA
Table II.20 Primary antibodies for Western Blot.
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secondary antibody dilution Company
goat anti-mouse IgG (H+L)-HRP conjugate 1:5000 Bio-Rad Laboratories
goat anti-rabbit IgG (H+L)-HRP conjugate 1:5000 Bio-Rad Laboratories
Table II.21 Secondary antibodies for Western Blot.
II.8. Generation of myristoylated PKCδ constructs
II.8.1 Cloning of myristoylated PKCδ constructs
To investigate the effects of targeting PKCδ to the plasma membrane, an 
NH2-terminal in-frame insertion of a myristoylation signal sequence was added as it 
has been described for PKCα [85]. Myristate, a 14-carbon saturated fatty acid, is 
covalently attached to the N-terminal glycine by the enzyme N-myristoyltransferase, 
usually during translation. To discriminate between endogenously and exogenously
expressed PKCδ and to determine transfection efficiencies and also successful 
membrane localization of MyrPKCδ by immunofluorescence, a sequence coding for 
the myc tag was added. To obtain the desired insert, PKCδ was amplified from 
pShooter PKCδ (a generous gift from Dr. Chaya Brodie, Henry Ford Hospital) and 
flanked with 5’-XbaI and 3’-EcoRI restriction sites. Primers used for amplification 
were as follows (restriction sites):
Forward primer (FW): 5’- CCAAGTCTAGAGCACCCTTCCTTCGCATCTCCTT -3’
Reverse primer (RV): 5’- TCCAAGAATTCCTATGCGGCCCCATTCAGATCC -3’
Since the resulting product will be used for cloning and subsequent protein 
expression from the resulting plasmid, it is desirable to minimize errors during 
replication. This can be achieved by using a proofreading enzyme, the Pfx Platinum 
Taq polymerase (Invitrogen, Carlsbad, CA). The PCR reaction was set up as follows:
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PCR reaction mix
10x PCR buffer 5 µl
dNTP (2.5 mM each) 4 µl
MgSO4 (50 mM) 1 µl
FW primer (10 mM) 2.5 µl
RV primer (10 mM) 2.5 µl
H2O 33 µl
Template 1 µl
Platinum® Pfx polymerase 1 µl
Table II.22 Components for PCR reaction buffer.
The reaction tube was then briefly mixed by gently tapping, spun down, and 
placed into a thermocycler. The following conditions were used for amplification:
PCR reaction
96°C 5 min
96°C 45 s
61°C 1 min 25 cycles
68°C 3 min
68°C 10 min
Table II.23 Conditions for PCR reaction.
One fifth of the reaction was run on a 1% agarose gel in Tris-Acetate-EDTA 
(TAE) buffer and DNA was stained with ethidium bromide and visualized with a 
BioRad Gel Doc system to verify the expected insert size of 2.1 kb (Figure II.3).
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Figure II.3 PCR amplification of PKCδ. The coding sequence of PKCδ was amplified from
the plasmid template and restriction sites were attached. Successful amplification is 
demonstrated by DNA agarose gel, and DNA was visualized with ethidium bromide. M = 
marker
In the next step, both PCR product and target vector were prepared. To this 
end, pCMV6-MyrPKCα (generous gift from Dr. Alex Toker, Harvard Medical School), 
was obtained (Figure II.4).
Figure II.4 Vector Map of MyrPKCα. 
M PKCδ
3 kb
2 kb
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The PCR product was purified using the QiaQuick PCR Purification Kit 
(Qiagen, Valencia, CA), and both the purified PCR product and pCMV6-MyrPKCα
were digested with EcoRI and XbaI (New England Biolabs, Ipswich, MA) for 2 h at 
37°C. The restriction digestion had the following effects: First, PKCα was removed 
from the pCMV6 plasmid while the myr sequence was retained. Second, digestion of 
the PKCδ PCR product and the vector created compatible ends that facilitate 
directional insertion of PKCδ. Following digestion, PCR fragment and vector were 
first visualized on a 1% agarose gel in TAE buffer (Figure II.5) and then gel-purified 
prior to ligation using the QiaQuick Gel purification Kit (Qiagen).
Figure II.5 Gel purification of digested DNA. DNA was loaded on an ethidium bromide 
containing 1% agarose gel and run at 110 V for 60 min. Left panel. PKCδ PCR. Right panel.
Successful removal of PKCα coding sequence from MyrPKCα. M = marker
Ligation was carried out in a 5:1 ratio of PCR-product:vector, using 50 ng of 
vector DNA and 78 ng of the PCR product. The formula used to calculate the 
required amount of PCR product when using 50 ng of vector DNA is
X ng PCR-DNA = 50 ng vector DNA * n(bp PCR-DNA)/n(bp vector DNA)
3 kb
2 kb
M PKCδ Vector
+PKCα
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For ligation of the PCR product and vector, the T4 ligase (New England 
Biolabs) was used in the presence of an ATP containing buffer in a total reaction 
volume of 20 µl at 16°C for 4 h and additional 30 min at room temperature. As a 
control for digestion efficiency, an additional tube was set up under identical 
conditions except that the PCR-product had been replaced with sterile water. 
From the experimental agar plate containing putative Myr PKCδ positive 
clones, eight colonies were picked and cultured for mini preparations (see section
II.8.2). Between 2 and 4 µg plasmid were used for restriction analysis using XbaI and 
EcoRI as described above and analyzed on a 1% agarose gel (Figure II.6).
Figure II.6 Digestion of PKCδ minipreps. After digestion with XbaI and EcoRI, only a subset 
of preparations show the correct pattern (clones 1, 2, and 5). DNA was run on a 1% agarose 
gel for 45 min at 110 V and stained with ethidium bromide. M = marker
From these, clones number 1, 2 and 5 were sequenced at the DNA 
sequencing facility of the Department of Genetics of the University of Pennsylvania 
(http://www.med.upenn.edu/dnaseq/). The primer used for sequencing anneals within 
the CMV promoter and has the sequence 5´-CGCAAATGGGCGGTAGGCGTG-3´. 
All three clones were identified to harbor the desired insert in the correct orientation. 
Clone #1 was then grown in a 250 ml LB/ampicillin culture and DNA was isolated 
using the EndoFree Plasmid Maxi Kit (see section II.8.2).
M PKCδ minipreps
Clones           1     2     3     4     5     6    7     8
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II.8.2 Transformation
The following reagents were used:
Product Company
LB Broth, Lennox, powder Thermo Fisher Scientific Inc.
One Shot® TOP10F´ Chemically 
Competent E. coli
Invitrogen
S.O.C. medium Invitrogen
Agar plates Ampicillin (50 µg/ml)
Cell Center Service Facility of the 
University of Pennsylvania
14 ml round bottom tubes BD Biosciences
EndoFree Plasmid Maxi Kit Qiagen Inc., Valencia, CA, USA
QIAprep Spin Miniprep Kit Qiagen Inc.
Table II.24 Materials for plasmid transformation.
Day 1: One Shot® TOP10F´ Chemically Competent E. coli were thawed on ice. 
For each transformation 25 µl of competent bacteria were used. 10 ng of plasmid 
(~ 2 µl) were added to the bacteria and incubated for 30 min on ice. Tubes 
containing competent bacteria and plasmid were placed in a 42°C waterbath for 30 
sec (heat shock). Bacteria were placed back immediately on ice for 5 min and 
incubated in 1 ml of S.O.C. medium for 1 h. After the incubation, 100 ?l of the 
bacteria suspension were evenly spread out on the agar plate with ampicillin and 
incubated at 37°C overnight.
Day 2: LB medium containing 50 µg/ml of antibiotic was prepared. 
a) Two colonies (clones) per transformation were picked and transferred into 
separate tubes containing 3 ml of LB/antibiotic, followed by incubation for 
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6-7 h (250 rpm, 37°C) (pre-culture). Then, 400 µl of the pre-culture were 
incubated over night in 200 ml LB/antibiotic (250 rpm, 37°C). In parallel, a 
bacteria glycerol stock of each colony was prepared. Therefore, the pre-
culture was mixed with autoclaved glycerol/LB 50% in a ratio 1:1 and 
stored at -80°C.
b) Two or more colonies per transformation were picked and transferred into 
separate tubes containing 4 ml of LB/antibiotic and grown by shaking
overnight (250 rpm, 37°C).
Day 3: a) Bacteria were centrifuged at 4,000 rpm for 1 h at 4°C. The bacteria pellet 
was either stored at -20°C or directly subjected to purification with the EndoFree 
Plasmid Maxi Kit to obtain endotoxin-free plasmid DNA or b) bacteria were 
centrifuged at 4,000 rpm for 15 min at 4°C and purified with the QIAprep Spin 
Miniprep Kit.
The EndoFree Plasmid Maxi Kit and QIAprep Spin Miniprep Kit (both Qiagen) 
were used according to the manual provided by the manufacturer. 
LB medium
LB Broth, Lennox, powder 20 g
dH2O to 1000 ml
Table II.25 Components for LB medium.
II.9 RNA interference (RNAi)
Double-stranded RNA (dsRNA) is an important regulator of gene expression 
in many eukaryotes. It triggers different types of gene silencing that are collectively 
referred to as RNA silencing or RNA interference (RNAi). RNAi is widely used as an 
experimental approach to silence the expression of proteins in cells. This method 
utilizes short dsRNAs, which guide sequence-specific degradation of complementary 
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or near-complementary target mRNAs by specific and distinct mechanisms [86]. Here, 
RNAi was used to deplete individual PKC isozymes from prostate cancer cells.
II.9.1 siRNAs for experimental gene silencing
The Silencer Negative Control siRNA#1 (AM4615) and Negative Control 
siRNA#2 (AM4644) were obtained from Applied Biosystems/Ambion Inc. (Austin, TX, 
USA). One hundred µl of 50 µM siRNA were diluted with 150 µl of storage buffer 1X
to obtain a concentration of 20 µM.
The siRNAs listed in Table II.26 and II.27 were purchased from Dharmacon 
Inc., now Thermo Fisher Scientific Inc.. The vial containing the siRNA as a powder 
was shortly centrifuged, reconstituted in storage buffer 1x to obtain a concentration of 
20 µM, mixed on an orbital shaker for 20 min at room temperature, and again shortly 
centrifuged. All siRNAs were aliquoted and stored at -20°C.
Product Target sequences of siRNA Used concentration
PKCα #1 CCAUCCGCUCCACACUAAA 120 pmol
PKCα #2 GAACAACAAGGAAUGACUU 120 pmol
PKCδ #1 CCAUGAGUUUAUCGCCACC 120 pmol
PKCδ #2 CAGCACAGAGCGUGGGAAA 120 pmol
PKCε #1 (ON-TARGETplus) GUGGAGACCUCAUGUUUCA 120 pmol
PKCε #2 (ON-TARGETplus) GACGUGGACUGCACAAUGA 120 pmol
BCL2A1 #1 GCAGUGCGUCCUACAGAUA 240 pmol
BCL2A1 #2 UAUCUCUCCUGAAGCAAUA 240 pmol
FOSL1 #1 GCUCAUCGCAAGAGUAGCA 240 pmol
FOSL1 #2 GAGCUGCAGUGGAUGGUAC 240 pmol
Table II.26 dsRNAi target sequences.
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For the following genes an ON-TARGETplus SMARTpool was used:
Gene Catalog number
Human FOSL1 L-004341-00
Human BCL2A1 L-003306-00
Human SERPINB2 L-010859-00
Human TRAF1 L-017438-00
Table II.27 ON-TARGETplus SMARTpool siRNAs for four selected genes.
dsRNAs were transfected into LNCaP cells using the Amaxa® Nucleofector®
as described in section II.4.1. Briefly, 2 x 106 cells were nucleofected with 120 or 240 
pmol of siRNA in 100 µl Nucleofector® solution R using the program T-009.
Experiments were carried out 12 or 48 h post-transfection. 
II.10 RNA isolation
II.10.1 RNA isolation with the Qiagen RNeasy Mini Kit
For RNA isolation 2x105 cells/6-well were plated or cells were transfected with 
siRNA as described in II.9.1. Experiments were carried out 12 or 48 h later and RNA 
was isolated by means of the Qiagen RNeasy Mini Kit (Qiagen) according to the 
manufacturer’s instructions.
II.10.2 RNA isolation for microarray
For microarray applications TRIzol® Reagent (Invitrogen) and the Qiagen 
RNeasy Mini Kit were combined. This method adds the tissue disruption and 
extraction power of TRIzol® to the purification and yield of RNeasy columns, while 
avoiding RNA precipitation.
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Homogenization and phase separation were conducted as described in the 
instructions for the use of TRIzol® (Invitrogen). Cells in 6-well plates were 
homogenized using 1 ml of TRIzol®. To separate the phases 200 µl of chloroform 
were added to each sample, incubated for 1 min at room temperature and vigorously 
shaken for 15 sec. Another incubation step of 2-3 min followed. Samples were 
centrifuged (12,000 x g, 4°C, 15 min). Subsequently, 250 µl of the colorless upper 
aqueous phase containing the RNA were transferred into a new tube and an equal 
volume of 70% ethanol was added. All following purification steps were performed as 
described in the Qiagen RNeasy instructions, including DNase digestion. RNA was 
??????? ??? ??? ??? of RNase-free water. One ??? ??? ????????-In (Applied 
Biosystems/Ambion?? ???? ??? ??? ???? ???????? ???? ?????? ???? ???????? ?????? RNA 
samples were stored at -80°C.
II.11 cDNA synthesis
In vitro complementary DNA or copy DNA (cDNA) is synthesized from RNA 
molecules in a reaction called reverse transcription (RT) using the enzyme reverse 
transcriptase. As there is no amplification involved, the number of cDNA molecules 
corresponds to the mRNA expression level for any given gene in a particular cell type 
or setting, i.e. treatment vs. control (see section II.13). 
The Reverse Transcription Reagent Master Mix (Applied Biosystems, 
Branchburg, NJ, USA) was prepared as shown in Table II.28. One µg of RNA and 
30.75 µl of the prepared Master Mix per sample were used. To adjust the volume to 
50 µl nuclease-free H2O (Genemate ISC Bioexpress) was used. 
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compound final concentration µl per reactions
10 reactions
add
10 x TaqMan® RT Buffer 1X 50 first
MgCl2 (25 mM) 5.5 mM 110
dNTP-Mix 500 µM each 100
Random hexamers 2.5 µM 25
RNase Inhibitor 0.4 U/µl 10 then
Multiscribe RT (50 U/µl) 1.25 U/µl 12.59
Table II.28 Composition of the Reverse Transcription Master Mix.
In the following order compounds were pipetted:
Nuclease-free H2O To 50 µl
Master Mix 30.75 µg
RNA 1 µg
Once the samples have been mixed and briefly centrifuged, the RNA was 
transcribed into cDNA using the following conditions in a MJ Research PTC-100 
Peltier Thermal Cycler (GMI Inc., Ramsey, MN, USA):
25°C 10 min
48°C 60 min
95°C 5 min
II.12 Reverse transcriptase real-time PCR
II.12.1 Experimental conditions
Real-time PCR or quantitative PCR (qPCR) is a variation of the standard PCR 
used to quantify DNA in a sample. Additionally, the relative expression of a particular 
mRNA sequence can be determined. This technique compares the expression 
between different genes or one particular gene expressed under different conditions 
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(i.e. treatment vs. control) relative to a specific housekeeping gene which in this 
study was 18S rRNAs (ribosomal RNAs). 
The amount of amplified product is measured at each cycle of the PCR, and 
PCR products from genes with higher expressions appear after fewer PCR cycles. 
To quantify the amplified product fluorescent probes are necessary. The used 
TaqMan® Gene Expression Assays (Applied Biosystem) are probes which all have a 
FAM™ reporter dye at the 5’ end of the TaqMan® MGB probe and a non-fluorescent 
quencher at the 3’ end of the probe. These probes hybridize to an internal region of a 
PCR product. In the unhybridized state, the proximity of the fluor and the quench 
molecules prevents the detection of fluorescent signal from the probe. During PCR, 
when the polymerase replicates a template on which a TaqMan® probe is bound, the 
5'-nuclease activity of the polymerase cleaves the probe. This decouples the 
fluorescent and quenching dyes. Thus, fluorescence increases in each cycle, 
proportional to the amount of probe cleavage.
In order to measure fluorescence while the temperature changes due to the
PCR conditions (see Table II.29) we used the 7300 Real-Time PCR System (Applied 
Biosystems). The data were analyzed using the 7300 System Software (Applied 
Biosystems).
Stage 1 50°C, 2 min Repetitions: 1
Stage 2 95°C, 10 min Repetitions: 1
Stage 3 95°C, 15 sec
60°C, 1 min
Repetitions: 40
The sample volume was 20 µl.
Data were collected at stage 3, step 2 (60°C,1 min). 
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II.12.2 Quantification with the 2-∆∆Ct method (comparative Ct method)
To quantify the results obtained by RT-PCR a comparative Ct threshold 
method was used. Here, the Ct values of the samples of interest and the control 
sample were normalized to the housekeeping gene 18S rRNAs and compared to 
each other. This 2-∆∆Ct method or comparative Ct method is defined as follows:
2-∆∆Ct = 2(∆Ct sample - ∆Ct reference)
∆Ct sample: Ct value for any sample normalized to 18S rRNAs
∆Ct reference: Ct value for the control normalized to 18S rRNAs
II.12.3 Materials and primers for RT-PCR using TaqMan®
Materials and TaqMan® Gene Expression Assays were obtained from 
Applied Biosystem, Foster City, CA, USA.
RT-PCR
7300 Real-Time PCR System
Software: 7300 System Software
MicroAmp® Optical Adhesive Film
MicroAmp® Optical 96-Well Reaction Plate with Barcode
Table II.29 Materials and equipment for RT-PCR.
probe reporter dye at the 5’ end
Eukaryotic 18S rRNA Endogenous Control VIC™ dye - MGB
BCL2A1 (Hs00187845_m1) FAM™ dye-MGB
FOSL1 (Hs00759776_s1) FAM™ dye-MGB
TRAF1 (Hs00194639_m1) FAM™ dye-MGB
SERPINB2 (Hs00234032_m1) FAM™ dye-MGB
PPP1R15A (Hs00169585_m1) FAM™ dye-MGB
Table II.30 TaqMan® Gene Expression Assays.
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II.13 DNA Microarray and Analysis of Array Data
Two experiments were performed, using the Affymetrix GeneChip® Human 
Genome U133A 2.0 Array (Affymetrix Inc., Santa Clara CA, USA), which represents 
the expression level of 18,400 transcripts and variants, including 14,500 well-
characterized human genes. Microarray services were provided by the Penn 
Microarray Facility, including quality control tests of the total RNA samples by Agilent 
Bioanalyzer and Nanodrop spectrophotometry. All protocols were conducted as 
described in the NuGEN Ovation manual and the Affymetrix GeneChip Expression 
Analysis Technical Manual. Briefly, 100 ng of total RNA was converted to first-strand 
cDNA using reverse transcriptase primed by a poly(T) oligomer that incorporated a 
synthetic RNA sequence. Second-strand cDNA synthesis was followed by ribo-SPIA 
(Single Primer Isothermal Amplification, NuGEN Technologies Inc., San Carlo, CA, 
USA) for linear amplification of each transcript. The resulting cDNA was transcribed 
into cRNA, which was also labeled with biotin during this process. Biotinylated cRNA 
was subsequently fragmented and assessed by Bioanalyzer. Then, ????? ?? of the
fragmented and labeled cRNA were added to Affymetrix hybridization cocktails, 
heated at 99ºC for 2 min and hybridized for 16 h at 45ºC to GeneChip® Human 
Genome U133A 2.0 Array. The microarrays were then washed at low (6X SSPE) and 
high (100 mM MES, 0.1 M NaCl) stringency and stained with streptavidin-
phycoerythrin. Fluorescence was amplified by adding biotinylated anti-streptavidin 
and an additional aliquot of streptavidin-phycoerythrin stain. A confocal scanner was 
used to collect the fluorescence signal after excitation at 570 nm. 
The first experiment that was carried out addressed the expression of genes 
at different time points after treatment with the phorbol ester PMA (100 nM). Cells 
were treated in triplicates with either vehicle or PMA (1 h, 100 nM) and total RNA was 
isolated at different times post-treatment (0, 4, 8, 12 and 24 h). Vehicle (ethanol)-
treated samples were collected at 24 h post-treatment. All samples (18 samples in 
total) were used for the experiment and hybridized to the array. CEL-files which 
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include the probe level data from the array were extracted from DTT-files. For 
background correction, normalization, and probe summarization the GCRMA 
algorithm (GeneChip Robust Multiarray Averaging) was applied to all 18 CEL-files. 
For this purpose, the program ArrayAssist Lite version 3.4 (Stratagene, LaJolla, CA) 
was used. In addition to the GCRMA signal we calculated Affymetrix absent (A), 
present (P) or marginal (M) MAS5 flags. Data were transferred to Spotfire (TIBCO, 
Palo Alto, CA) in order to filter and to visualize the data. Data were filtered retaining 
only those probe sets that were flagged as present in at least two of the 18 samples. 
For statistical analysis the flag-filtered data were evaluated using Partek Genomics 
Suite (Partek Inc., St Louis, MO). Log2 ratios for each probe set in each condition 
were calculated versus ethanol (vehicle). A one-way ANOVA was used across the 6 
conditions. Additionally, we calculated the five pairwise contrasts between each 
PMA-treated condition and the ethanol control. This yielded a p value for the Anova 
and a p value and log2 ratio for each of the pairwise comparisons for all of the filtered 
probe sets. For these six p values the false discovery rate (FDR)-corrected p value 
was calculated according to the method of Benjamini and Hochberg [87, 88]. 
Additionally, the maximum of the absolute value of each of the log2 ratios was 
calculated. Genes were considered for further evaluation if their FDR-corrected p 
values for the ANOVA were ≤ 0.001 and the maximum absolute value was at least 1 
(± 2 fold in at least one of the five pairwise comparisons). These criteria yielded 4949 
probe sets. The procedure is summarized in Fig. II.7.
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Fig. II.7 Gene expression analysis at a glance. Flow chart of data evaluation and selection 
criteria.
The second experiment that I carried out addresses PKC isoform-specific 
regulation of expression. Cells transfected separately with two different RNAi 
duplexes for either control or each of the PKC isoforms (PKCα, δ, ε) were treated 
with vehicle (1h, ethanol) or PMA (1 h, 100 nM), and total RNA was isolated 4 h post-
treatment. Experiments were conducted in triplicates, resulting in a total of 48 
samples. RNA from all 48 samples was prepared and subjected to microarray 
analysis. CEL files were background corrected, normalized, summarized and 
transformed as described above. A two-way ANOVA (treatment, RNAi) was 
calculated. Triplicate samples were averaged and a p value and a log2 ratio was 
calculated for each PKC RNAi relative to control RNAi, both for vehicle and PMA 
conditions. Only genes with a minimum induction by PMA of two fold were filtered 
(log2 ratio PMA vs. vehicle ???????????????????????????????
Microarray data from 
triplicate samples
Background correction
Normalization
Summarization
Selection of genes of interest
- Assessment of statistical significance with 2-Way ANOVA
and Benjamini and Hochberg false discovery rate (FDR)
- Selection of genes with ? 2 fold change (PMA/vehicle)
- Categoriziation of selected genes by Gene Ontology
biological processes
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II.14 Validation of data by quantitative RT-PCR
Fold changes were referred to samples transfected with control siRNA and 
treated with vehicle. GCRMA values were normalized to GAPDH. In order to analyze 
PKCδ-specific genes two different RNAis for PKCδ (siRNA sequences see Table 
II.26 in II.9.1) were used. For control and the PKCα and PKCε isoforms one specific 
siRNA (siRNA #1 of each PKC; siRNA sequences see Table II.26 in section II.9.1) 
was used.
II.15. Statistical analysis
All experiments were performed three times. For statistical analysis, two tailed 
Student’s t-test for equal sample variance was used. A p value <0.05 was considered
as significant. The results are represented as the mean value ± S.E.M..
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III RESULTS
III.1 Phorbol ester and bryostatin have opposing effects in LNCaP cells 
III.1.1 PMA induces apoptosis in the prostate cancer cell line LNCaP
Most PKC agonists, including phorbol esters, DAGs, and ingenol-3-angelate 
(PEP005), bind to the C1 domains in cPKCs and nPKCs leading to kinase activation
in vitro. In androgen-dependent prostate cancer cells, these PKC activators induce a
strong apoptotic response [57, 81, 89, 90]. 
To first confirm previous findings, the apoptotic effect of PMA on LNCaP cells
was assessed. To that end cells were treated with vehicle or different concentrations 
of PMA and the percentage of apoptotic cells determined. Apoptosis in response to 
PMA increased in a dose-dependent manner (Fig. III.1). In all future experiments the 
PMA concentration was kept constant at 100 nM as the maximal apoptotic response 
had been achieved at this concentration in previous work [81].
Figure III.1 PMA induces apoptosis in LNCaP cells in a dose-dependent manner. LNCaP 
cells were treated with vehicle or various concentrations of PMA as indicated for 1 h and then 
washed extensively with medium. Apoptosis was assessed 24 h later by DAPI staining. Data 
represent the mean ± S.E.M. of three independent experiments.
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III.1.2 The C1 domain ligand bryostatin 1 fails to induce cell death and inhibits
PMA-induced apoptosis in LNCaP cells 
Previous studies showed that long-term treatment (24-72 h) of LNCaP 
prostate cancer cells with 10 nM bryostatin 1, another C1 domain ligand for PKCs, 
does not affect LNCaP cell viability. Such long-term treatment causes a marked 
down-regulation of PKC isozymes, primarily PKCα [91]. The main interest of this 
study was focused on the effects of short-term treatment with bryostatin 1 on LNCaP 
cells, an effect that should be independent of PKC down-regulation. Indeed, short 
treatment (1 h) of LNCaP cells with bryostatin 1 (0.1-100 nM) did not appreciably 
change the expression of PKCα, PKCδ, or PKCε, which are the C1 domain 
containing PKC isoforms expressed in these cells (Fig. III.2A).
As previously reported [58], a 1 h treatment with PMA caused a marked 
apoptotic response in LNCaP cells. On the other hand, bryostatin 1 failed to cause 
apoptosis at all concentrations tested (0.1-100 nM) under similar experimental 
conditions. Moreover, co-incubation of bryostatin 1 with PMA inhibited the apoptotic 
effect of the phorbol ester in a dose-dependent manner (Fig. III.2B and III.2C). In 
agreement with a previous study [91], a 24 h treatment with bryostatin 1 also failed to 
promote LNCaP apoptotic cell death. Representative micrographs of LNCaP cultures 
and nuclear DAPI stainings in response to the different treatments are shown in Fig. 
III.2C. These results suggest that bryostatin 1 acts as a functional antagonist of PMA-
induced apoptosis in LNCaP prostate cancer cells.
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A B
C
Figure III.2 Short-term bryostatin 1 treatment prevents PMA-induced apoptosis in 
LNCaP cells. Panel A. LNCaP cells were treated with different concentrations of bryostatin 1 
(0.1-100 nM, 1 h) and subjected to Western blot analysis using specific antibodies for PKC 
isozymes. Panel B. LNCaP cells were treated for 1 h with PMA or bryostatin 1 alone or in 
combination at the concentrations indicated in the figure, and the percentage of apoptotic 
cells determined 24 h later. The effect of 24 h of bryostatin 1 treatment is also shown. Data 
represent the mean ± S.E.M. of three independent experiments. Panel C. Representative 
micrographs of LNCaP cell cultures (left panel) and DAPI stainings (right panel), after 
treatment with PMA and/or bryostatin 1 (100 nM). Apoptotic cells are indicated with arrows.
III.1.3 Bryostatin 1 does not affect the expression of survival factors or the
phosphorylation status of Akt or p38 
Apoptosis is a well orchestrated process and is controlled by multiple 
pathways, both pro- and anti-apoptotic. These pathways need to be perfectly 
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balanced, and imbalances can result in premature cell death of an otherwise intact 
cell or to apoptotic resistance in a cell that normally needs to be eliminated from the 
organism, i.e. cancer cells. Well studied factors that contribute to the apoptotic 
resistance are MCL1, BCL-XL and BCL-2 [92, 93]. Therefore, LNCaP cells were 
treated with PMA alone or in combination with bryostatin 1 as described above and 
cells lysed at different times, and subjected to Western blot analysis using antibodies 
against the aforementioned factors. The results shown in Figure III.3 demonstrate 
that expression of MCL1, BCL-XL, and BCL-2 was not increased and therefore are 
not likely to contribute to the anti-apoptotic effect of bryostatin 1. 
Figure III.3 PMA-induced expression of MCL1, BCL-XL, and BCL-2 does not change 
after treatment with bryostatin 1. LNCaP cells were treated at the indicated time points with 
100 nM PMA alone or in combination with 10 nM bryostatin 1 and subjected to Western blot 
analysis. 
In addition to these factors, an interesting question was whether changes in 
the phosphorylation status of Akt and p38 occur. It has been described previously 
that phosphorylation of these factors is altered in LNCaP cells upon treatment with 
PMA [58]. Western blot analysis shows clearly that Akt was rapidly dephosphorylated 
after treatment with PMA, and phospho-p38 levels increased over time, while total 
levels of these proteins remained unchanged. When cells were treated with 
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bryostatin 1 either alone or in combination with PMA, the kinetics of phospho-Akt 
dephosphorylation and the phosphorylation of p38 were not affected (Fig. III.4A and 
III.4B).
A
B
Figure III.4 The PMA-induced phosphorylation status of p38 and Akt is not affected 
upon treatment with bryostatin 1. LNCaP cells were treated with 100 nM PMA, 10 nM 
bryostatin 1, alone or in combination at the indicated time points. Proteins were subjected to 
Western Blot analysis. Panel A. Western Blot analysis for p38. Panel B. Western Blot analysis 
for Akt.
III.1.4 Conditioned medium (CM) from bryostatin 1-treated LNCaP cells inhibits
PMA-induced apoptosis in na?ve LNCaP cells 
As shown in Figure III.3 and III.4A and 4B neither MCL-1, BCL-XL or BCL-2
nor changes in the phosphorylation status of Akt or p38 are implicated in the anti-
apoptotic effect of bryostatin 1. Therefore, a more broad-based approach was 
chosen to clarify the anti-apoptotic effect of bryostatin 1 and the role of factors 
secreted by LNCaP cells upon treatment with PMA. Previous studies from our 
laboratory have shown that PMA-induced apoptosis in LNCaP cells is mediated by 
the autocrine release of death factors primarily TNFα. Therefore, the failure of 
bryostatin 1 to promote LNCaP cell apoptosis might relate to its inability to induce the 
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secretion of death factors. Also it could be possible that bryostatin 1 alters the pattern 
of secreted factors, thereby inhibiting PMA-induced apoptosis. To this end, CM was 
prepared as described in the Materials and Methods section II.3.3. As shown in 
Figure III.5, treatment with CM collected from cells treated with PMA (CM-PMA) 
resulted in increased apoptosis of recipient LNCaP cells. In contrast, CM collected 
from cells treated with bryostatin 1 + PMA (CM-Bryo1+PMA) did not yield an 
apoptotic response when added to na?????????????????
Figure III.5 CM from bryostatin 1-treated cells inhibits apoptosis in LNCaP receptor 
cells. LNCaP cells were treated with bryostatin 1 (10 nM) and/or PMA (100 nM), or vehicle. 
CM was collected 24 h later and added to a naïve culture of LNCaP cells. The percentage of 
apoptotic cells was determined 24 h later. Data represent the mean ± S.E.M. of three 
independent experiments, *p<0.05.
Again, the common and well studied signaling cascades of the p38/MAPK, 
Akt and, in addition, the JNK pathways were investigated. To exclude that bryostatin 
1 influences these pathways through an altered composition of the CM, time-course 
experiments with CM were performed. Time-courses were chosen to be longer than 
in previous experiment to include late events. No changes in the phosphorylation 
status of p38, JNK or Akt were observed. (Fig. III.6A). Therefore, it appears that 
these signaling pathways are regulated by PMA independently of bryostatin 1-
induced changes of the CM.
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We also tested if the time-course of p38 phosphorylation was shortened upon 
treatment with PMA and bryostatin 1 as compared to treatment with PMA alone. 
However, no differences in the phosphorylation of p38 were observed over 8 hours 
(Fig. III.6B).
A
B
Figure III.6 CM-Bryo1+PMA does not alter the phosphorylation status of p38/MAPK, 
JNK, and Akt. Panel A. LNCaP cells were treated with 10 nM bryostatin 1 ± 100 nM PMA for 
1 h and CM was collected 24 h later. Fresh LNCaP cells were then treated with CM and 
harvested at indicated time points. Protein lysates were subjected to Western Blot analysis. 
The phosphorylation status of both JNK and p38 as well as of Akt was not altered when cells 
were treated with CM from LNCaP cells treated with PMA alone or in combination with 
bryostatin 1. Panel B. LNCaP cells were treated with 10 nM bryostatin 1 ± 100 nM PMA for 1 
h and CM was collected 24 h later. Fresh LNCaP cells were then treated with CM and 
harvested at indicated time points. p38 remains phosphorylated even after 8 h of treatment. 
No differences were observed between cells receiving CM from PMA or bryostatin 1 + PMA.
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III.1.5 Analysis of the secreted factors to the CM using a cytokine array does
not reveal significant changes upon treatment with bryostatin 1
In order to identify changes in the release of cytokines, chemokines and 
growth factors into the medium after treatment with bryostatin 1 (10 nM) and/or PMA 
(100 nM), a commercial cytokine array (Ray Biotech, No. 5) was used. Membranes 
were incubated with CM from LNCaP cells subjected to the different treatments or 
vehicle and the relative changes in cytokine expression was determined. Using the 
Map of RayBio Human Cytokine Antibody Array 5 the cytokines of the array could be 
identified (Table. III.1). No major changes upon treatment with bryostatin 1 were 
found (Fig. III.7A). The densitometric evaluation of several cytokines is shown in Fig. 
III.7B. All samples on one membrane were normalized to the intensity of the internal 
control. In a second step, the relative intensities were normalized to the samples
treated with CM-Vehicle, and the corresponding samples were then displayed as 
fold-changes compared to vehicle-treated cells. As shown in Fig. III.7B, there was a 
marked increase in the release of a broad range of secreted cytokines to CM in 
response to PMA. However, there were no relevant differences in these cytokines 
from CM-Bryo1+PMA, making these factors unlikely to be candidates for the
inhibitory effect of Bryo1 on PMA-induced apoptosis in LNCaP cells.
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A B C D E F G H I J K
1 Pos Pos Pos Pos Neg Neg ENA-78 GCSF
GM-
CSF
GRO GRO-α
2 I-309 IL-1α IL-1β IL-2 IL-3 IL-4 IL-5 IL-6 IL-7 IL-8 IL-10
3
IL-12 
p40p70
IL-13 IL-15 IFN-γ MCP-1 MCP-2 MCP-3 MCSF MDC MIG MIP-1β
4 MIP-1β RANTES SCF SDF-1 TARC TGF-β1 TNF-α TNF-β EGF IGF-I
Angio-
genin
5
Onco-
statin M
Thrombo-
poietin
VEGF
PDGF-
BB
Leptin BDNF BLC Ck β 8-1 Eotaxin Eotaxin-2 Eotaxin-3
6 FGF-4 FGF-6 FGF-7 FGF-9
Flt-3 
Ligand
Fract-
alkine
GCP-2 GDNF HGF IGFBP-1 IGFBP-2
7 IGFBP-3 IGFBP-4 IL-16 IP-10 LIF LIGHT MCP-4 MIF MIP-3 α NAP-2 NT-3
8 NT-4
Osteo-
protegerin
PARC PIGF
TGF-β
2
TGF-β
3
TIMP-1 TIMP-2 Neg Pos Pos
Table III.1 Map for RayBio® Human Cytokine Antibody Array 5 (adapted from 
www.raybiotech.com).
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CM-Bryo1
CM-PMA
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B
Figure III.7 The cytokine array does not reveal any major changes in the secretion of 
cytokines upon treatment with bryostatin 1. Panel A. LNCaP cells were treated with 10 nM 
bryostatin 1 and/or 100 nM PMA or vehicle. CM was collected 24 h later and expression of 
cytokines determined with a cytokine array. Array Membranes were incubated for 2 h with 1 
ml of CM from cells treated with PMA or bryostatin 1 alone or in combination, and detection 
was achieved by enhanced chemiluminescence. Panel B. Changes in the concentrations of 
selected cytokines in the cytokine array, as determined by densitometry, did not show
relevant differences in cytokine concentrations in the medium of cells treated with Bryo1 + 
PMA compared to cells treated with PMA alone.
One caveat of this approach might be the limited dynamic range of the HRP-
based detection system as compared to fluorescent detection systems [94]. In other 
words, a change in protein concentration on the lower detection limit might not be 
detected because proteins present at high levels (such as IL-8) are at detection 
ranges in which saturation already occurs. Therefore, we decided to focus on TNFα
as an interesting candidate cytokine using ELISA technology. As indicated before, 
TNFα is an important factor released by LNCaP cells when treated with PMA [57].
Moreover, it was shown to be involved in triggering the pro-apoptotic signaling 
cascade in this cell system [57].
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III.1.6 Bryostatin 1 prevents PMA-stimulated release of TNFα from LNCaP cells 
Previous studies have established that PMA promotes the release of death 
factors from LNCaP cells, primarily TNFα. RNAi depletion or inhibition of TACE (the 
enzyme responsible for TNFα shedding [95]), neutralization of TNFα in the CM, or 
blockade/depletion of TNFα receptors, markedly reduces PMA-induced apoptosis in 
LNCaP cells, arguing for a critical involvement of this autocrine loop in the death 
effect of the phorbol ester [57]. To determine if autocrine mechanisms are involved in 
the inhibition of PMA-induced apoptosis by bryostatin 1, the effect of bryostatin 1 on 
TNFα release from LNCaP cells was examined. As shown in Fig. III.8A, TNFα
specific ELISA clearly demonstrates that unlike PMA, bryostatin 1 treatment failed to 
induce any measurable release of TNFα from LNCaP cells, and more importantly, it 
essentially blunted TNFα release by PMA.
In order to determine whether reduced secretion of TNFα is a critical 
determinant for the impaired apoptotic response of PMA in the presence of bryostatin 
1, a rescue approach by adding exogenous TNFα to the CM was pursued. The 
assumption for this experiment was that by supplementing this cytokine to CM-
Bryo1/PMA to levels similar as those normally observed in CM-PMA, it should be 
possible to restore the apoptotic response. A caveat in this experiment, is that, as 
shown in Fig. III.8C, the recovery of TNFα was less than 20% of the amount added. 
Possible reasons for this reduced recovery may be decreased stability and/or 
misfolding of the synthetic TNFα. Importantly, addition of exogenous TNFα was able 
to rescue the pro-apoptotic effect of CM-Bryo1/PMA in a concentration-dependent 
manner (Fig. III.8B). Based on the linear correlation established between the added 
and measured TNFα concentrations in the medium we were able to estimate the 
actual TNFα concentrations in CM-Bryo1/PMA. Data clearly show that complete 
rescue could be achieved at concentrations of TNFα similar to those present in CM
(compare with Fig. III.8A). 
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A
B
C
Figure III.8 Bryostatin 1 prevents the release of TNFα from LNCaP cells. Panel A. TNFα
levels were measured by ELISA in CM collected 24 h after the different treatments. Data 
represent the mean ± S.E.M. of three independent experiments. Panel B. LNCaP cells were 
treated with vehicle, bryostatin 1, PMA, or bryostatin 1 in combination with PMA at the 
concentrations indicated in the figure. CM was collected 24 h later, supplemented with TNFα
at the indicated concentrations, and added to naïve LNCaP cells. After 24 h the percentage of 
apoptotic cells was determined. The concentrations of TNFα in CM calculated according to 
the relation given in Panel C is also shown. Data represent the results of three independent 
experiments (mean ± S.E.M.). Panel C. Determination of TNFα concentrations by ELISA in 
medium after supplementation with exogenous TNFα.
T
N
F α
[p
g
/m
l]
Veh Bryo1 PMA Bryo1 + PMACM
0
50
100
150 *
T
N
F α
[p
g
/m
l]
Estimated TNFα in CM [ng/ml] 
%
 A
p
o
p
to
ti
c 
ce
lls
Added TNFα in CM [ng/ml] - - 10    10 - - 0.1     1      10 
Veh Bryo1 Bryo1 PMA Bryo1 + PMAVehCM
0
10
20
30
40
- - 1.8   1.8 - - 0.02   0.18  1.8 
%
 A
p
o
p
to
ti
c 
ce
lls
T
N
F
α
in
 m
ed
iu
m
 [
p
g
/m
l]
Added TNFα [ng/ml]
y = 180.2x + 2.4
R2 = 0.9999
0
400
800
1200
1600
2000
0 2 4 6 8 10 120 2 4 6 8 10 12
40
800
1600
200
T
N
F
α
in
 m
ed
iu
m
 [
p
g
/m
l]
III RESULTS 83
III.1.7 PKCδ is a key regulator of PMA-induced TNFα release from LNCaP cells 
A previous report has shown that the ability of bryostatin 1 to impair PMA-
induced apoptosis is related to its ability to down-regulate PKCα from LNCaP cells, 
although unlike the studies presented here this occurred upon long-term (24-72 h) 
treatment [91]. Also, a key role has been assigned to PKCδ in PMA-induced 
apoptosis [58]. Therefore, in the present studies this issue was explored in more 
detail by means of a RNAi approach. The three PMA-responsive PKCs expressed in 
LNCaP cells were silenced using two different siRNA duplexes for each PKC isoform, 
which minimized the possibility of “off-target” effects of RNAi. Isozyme-specific 
depletion for each PKC was successfully achieved with either duplex relative to cells 
transfected with control siRNA (Fig. III.9A). These experiments revealed that the 
apoptotic effect of PMA was substantially reduced in PKCδ-knockdown LNCaP cells, 
but not in cells in which either PKCα or PKCε were depleted (Fig. III.9B). A greater
apoptotic effect of PMA was observed in PKCε-depleted LNCaP cells, consistent with 
its pro-survival effect in this model [96]. Most importantly, only PKCδ depletion could 
significantly impair TNFα release by the phorbol ester, while depletion of either PKCα
or PKCε failed to block secretion of the death factor (Fig. III.9C). These data not only 
suggest that PKCδ is crucial for PMA-induced TNFα release in LNCaP cells, but it 
also argues in favor of PKCδ as the main PKC implicated in the protection of PMA-
induced apoptosis by bryostatin 1.
A
PKCα
PKCδ
PKCε
siRNA C      α #1    α #2    δ #1    δ #2    ε #1     ε #2
β-actin
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B
C
Figure III.9 PKCδ is essential for TNFα release induced by PMA. LNCaP cells were 
transfected with two different siRNA duplexes (#1 or #2) for each PKC isoform or a control 
siRNA (240 pmol). After 48 h, cells were treated with PMA (100 nM, 1 h). Panel A. Western 
Blot for PKCα, PKCδ, and PKCε 48 h after transfection. Panel B. Effect of individual PKC 
isozyme depletion on PMA-induced apoptosis, as determined 24 h after treatment. Data 
represent the mean ± S.E.M. of three independent experiments, *p<0.05 vs. control siRNA. 
Panel C. TNFα levels in CM from vehicle- or PMA-treated LNCaP cells subject to PKC 
isozyme RNAi depletion. Data represent the mean ± S.E.M. of three independent experiments, 
*p<0.05 vs. control siRNA.
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III.1.8 Bryostatin 1 selectively inhibits the translocation of PKCδ to the plasma
membrane in LNCaP cells
At this point, the data obtained so far called for the question whether 
bryostatin 1 could induce changes in the subcellular localization of PKCδ. It is well 
established that translocation of PKC isozymes is a hallmark of enzyme activation
[97]. It is tempting to speculate that the failure of bryostatin 1 to induce apoptosis in 
LNCaP cells may relate to its failure to translocate PKCδ to the plasma membrane, 
which may ultimately lead to the inability to release TNFα. To this end, translocation 
of PKCs was assessed using GFP-fused PKCs. LNCaP cells were transfected with 
pEGFP-N1-PKCα, pEGFP-N1-PKCδ, or pEGFP N1-PKCε and 48 h after transfection, 
cells were treated with PMA or bryostatin 1, alone or in combination. Localization of 
the GFP-fused PKCs was determined by confocal microscopy. PMA redistributed 
PKCα and PKCε to the plasma membrane, while PKCδ was dually translocated to 
the plasma and nuclear membranes (Figs. III.10C, 10G, and 10K). Similar patterns of 
translocation for these PKCs have been reported in various cell types [81, 82, 98]. 
Like PMA, treatment with bryostatin 1 caused significant translocation of PKCα and 
PKCε to the cell periphery, although the effect was less pronounced for PKCα (Fig. 
III.10B and J). In contrast, bryostatin 1 caused a pronounced translocation of PKCδ
to the nuclear membrane, but remarkably, translocation to the plasma membrane 
could not be readily detected (Fig. III.10F). Co-treatment of LNCaP cell with PMA and 
bryostatin 1did not affect the translocation of PKCα and PKCε to the cell periphery
(Fig. III.D and L). In contrast, under these conditions peripheral translocation of PKCδ
by PMA was significantly reduced in cells treated with bryostatin 1, whereas 
accumulation of PKCδ at the nuclear membrane remained essentially unaffected (Fig. 
III.10H). These findings demonstrate a different subcellular relocalization of PKCδ
depending on the ligand used for treating LNCaP cells. Most importantly, they reveal 
that bryostatin 1 has the ability to prevent the translocation of PKCδ to the plasma 
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membrane without significantly altering the distribution of other PKCs. It is therefore 
conceivable that translocation of PKCδ to the plasma membrane is a pre-requisite for 
the induction of apoptosis in LNCaP cells by PKC activators.
Figure III.10 Bryostatin 1 impairs PMA-induced peripheral translocation of PKCδ in 
LNCaP cells. LNCaP cells expressing GFP-PKCα, GFP-PKCδ, or GFP-PKCε were 
stimulated for 20 min with vehicle, 100 nM PMA or bryostatin 1, alone or in combination. 
Localization was determined by confocal microscopy. Representative micrographs are shown. 
Similar results were observed in multiple cells in at least three individual experiments.
III.1.9 Translocation of PKCδ to the plasma membrane is essential for the
induction of apoptosis in LNCaP cells
Localization of PKC isozymes is key for determining the nature of the cellular
response to PKC activators. PKCs can differentially translocate to multiple 
compartments in a cell type-specific manner, leading ultimately to a differential 
access to substrates or accessory interacting proteins [99, 100]. The data of the 
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PKCα
PKCε
PKCδ
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I J K L
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present studies point to plasma membrane redistribution of PKCδ as an essential 
step for PMA-induced apoptosis in LNCaP cells. To test this hypothesis, a construct 
in which PKCδ was fused at the N-terminus to a myristoylatation signal sequence
(myr) and at the C-terminus to a myc-tag was generated. PKCδ expressed from this 
construct will be targeted to the plasma membrane through its myristoylated N-
terminus, while detection could be achieved through staining or immunoblotting 
against the C-terminal myc tag. LNCaP cells were transfected with plasmids 
encoding either wild-type PKCδ, which localizes essentially in the cytoplasm 
(PKCδcyto), or the membrane-targeted PKCδ (PKCδmyr), and apoptosis assessed 
24 h later. Transfection efficiencies were ~15% as determined by the fraction of myc-
tag positive cells. Expression by Western blot is shown in Fig. III.11A. Upon ectopic 
expression of PKCδcyto in LNCaP cells no measurable apoptotic response could be
detected. In contrast, ectopic expression of PKCδmyr resulted in significant cell death 
(Fig. III.11B). To confirm the localization of PKCδmyr at the plasma membrane, 
confocal microscopy was performed. As shown in Fig. III.11C, this modified form of 
the kinase localized exclusively in the cell periphery, while PKCδcyto was found 
essentially in the cytoplasm of LNCaP cells. Thus, targeting PKCδ to the plasma 
membrane is sufficient to promote apoptosis in LNCaP cells. Taken together, the
data presented here strongly argue that the lack of apoptosis in response to 
bryostatin 1 and the abrogation of PMA-induced apoptosis by bryostatin 1 are due to 
the inability of PKCδ to translocate to the plasma membrane.
III RESULTS 88
A B
C
Figure III.11 Targeted localization of PKCδ to the plasma membrane induces apoptosis 
in LNCaP cells. LNCaP cells were transfected with myc-tagged vectors encoding PKCδcyto,
PKCδmyr, or empty vector as a control. Panel A. Expression was determined by Western blot 
using an anti-myc-tag antibody. Panel B. Percentage of apoptotic cells 24 h after transfection. 
Data represent the mean ± S.E.M. of three independent experiments. Panel C. Localization of 
PKCδcyto and PKCδmyr in LNCaP cells 24 h after transfection. Transfection efficiency was 
~15%.
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III.2. Genome-wide expression analysis reveals PKCδ as master regulator of
transcription in LNCaP cells
III.2.1 Inhibition of protein synthesis by cycloheximide significantly decreases
PMA-induced apoptosis
Although PKCs are known to play an important role in the regulation of gene 
expression through TPA/PMA-responsive elements in gene promoters, our
understanding of how individual PKC isozymes control gene expression is poor. The 
well-established differential effects of PKC isozymes in survival and apoptosis in 
prostate cancer cells prompted us to investigate whether transcriptional regulation 
might be involved in phorbol ester induced apoptosis in prostate cancer cells. To 
address this question, LNCaP cells were treated with the inhibitor of protein synthesis 
cycloheximide (50 µM) prior and during the exposure to PMA (100 nM, 1 h). The 
efficiency of cycloheximide was confirmed by its ability to inhibit the induction of the 
cell cycle regulator p21 (Fig. III.12A). Notably, the apoptotic effect of PMA was 
significantly reduced from 27.9 ± 3.1% in vehicle-treated cells to 15.6 ± 0.7% in 
cycloheximide-treated cells (Fig. III.12B). Thus, the inhibition of de novo protein 
synthesis significantly decreased the apoptotic response by 44%. These results 
argue for a potential involvement of transcriptional mechanisms in the induction of 
apoptosis by PMA. Therefore, global gene expression analyses were carried out to 
address the following two questions: First, what is the overall change in gene 
expression upon treatment with PMA and when do these changes occur; and second, 
what is the relative contribution of PKC isozymes to the control of gene expression? 
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A B
Figure III.12 Inhibition of protein synthesis reduces PMA-induced apoptosis. Panel A.
Cycloheximide (Chx) inhibits the induction of p21. Panel B. LNCaP cells were treated with 50 
?????? 40 min prior to and during stimulation with 100 nM PMA. Data represent the mean ± 
S.E.M. of three independent experiments, *p<0.05. 
III.2.2 PMA rapidly induces changes in gene expression levels
To address the first question, a time-dependent analysis of transcriptional 
changes in response to PMA (100 nM, 1 h) was carried out as described in section 
II.13. Applying the criteria for significance as mentioned in the Material and Methods 
section (Fig. II.7), 4949 genes displayed a significant change ? 2-fold in PMA-treated 
LNCaP cells compared to vehicle (ethanol) at different time points after treatment. 
We observed a variety of patterns of changes in expression over time, which allowed 
the categorization into either of the following groups: up- vs. down-regulated, and 
early- vs. late-regulated genes (Fig. III.13A). Interestingly, most of all altered genes 
were found to be regulated within the first 4 h after stimulation. There was a striking 
difference between the number of genes that were transiently regulated (Fig. III.13B, 
Panels 1-3) and those that exhibited sustained changes (Fig. III.13B, Panels 4-6). 
The latter represents the time-course of regulation for the majority of genes.
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Figure III.13 Genome-wide expression analysis reveals different temporal patterns of 
gene expression with the majority of changes in gene expression occurring 4 h after 
PMA treatment. Panel A. Expression levels change over time. The heat map shows 4949 
genes which are significantly altered 0, 4, 8, 12, and 24 h after treatment with PMA. The 
number of genes with changes in expression levels differs between time points. Panel B.
Genes can be classified into early (0-4 h) and late (8-24 h) regulated genes. Genes were 
filtered with respect to transient (panels 1-3) or sustained (panels 4-6) changes. In both sets, 
the majority of changes in gene expression occurs 4 h after PMA treatment.
III.2.3 Selection of PMA-regulated genes according to their Gene Ontologies
To further characterize the distribution of PMA-regulated genes across 
biological functions, genes were categorized according to six Gene Ontology 
biological processes, which led to functional classification of 1280 genes. Out of 
these, 7% are involved in apoptosis/survival, 17% in proliferation, 13% in 
differentiation, 4% in oncogenesis, 22% are transcription factors, and 37% are 
encoding for signal transduction molecules (Fig. III.14A). In addition, these 1280 
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genes were classified into early- and late-regulated genes. In addition and in line with 
previous analysis conducted during these studies, most of the regulated genes were 
altered within 4 h after treatment with PMA (Fig. III.14B). 
A
B
Figure III.14 Classification of regulated genes according to their biologic functions. 
Panel A. The 4949 PMA-regulated genes shown in the heat map were filtered according to 
their Gene Ontology biological processes (GO) as indicated, resulting in a functional 
classification of 1280 genes. Most of the PMA-regulated genes are related to transcription 
factors (TF) and signal transduction (ST) compared to apoptosis/survival (AP/S), 
differentiation (DF), oncogenesis (OG), or proliferation (P). Panel B. The 1280 genes 
categorized according to their GO were further classified into early (0-4 h) and late (4-24 h) 
regulated genes. The number of regulated genes at indicated time points after PMA treatment 
shows that unlike early responsive genes, regulation of late regulated genes lacks a dynamic 
over time.
III.2.4 Isozyme-specific depletion of PKCs in LNCaP cells
As individual PKC isozymes exert different functions in prostate cancer cells, 
it is desirable to determine whether the three PMA-responsive PKC isozymes present 
in LNCaP cells (PKCα, PKCδ and PKCε) could potentially regulate different subsets 
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of genes. To this end, a genome-wide expression analysis in LNCaP cells in which 
each individual PKC isozyme was depleted by RNAi was carried out. Various RNAi 
duplexes were tested and the two most effective and specific for each PKC isozyme 
were selected for these studies, which minimized the chances of “off-target” effects of 
the RNAi. Two different control RNAi sequences were also used. As shown in Fig. 
III.15, a nearly complete depletion for all RNAi duplexes was achieved, and 
importantly, knock-down was PKC isozyme-specific. 
Figure III.15 Depletion of PKCs is isozyme specific. Western blot analysis conducted 48 h 
post transfection of LNCaP cells with two different RNAi duplexes (120 pmol) shows highly 
specific knockdown of each PKC isozymes.
III.2.5 Reproducibilty between two independent microarray experiments
To verify the reproducibility of the microarray experiments, genes regulated 
by PMA at 4 h after treatment in the first microarray experiment were compared with 
those of the 4 h time point from cells transfected with non-specific control siRNA in 
the second microarray experiment. Despite this difference between the samples, 
among the 50 most regulated genes a concordance of 96% between the two 
experiments was found, thus indicating a high degree of reproducibility (Table III.2).
PKCα
control PKCα PKCδ PKCε
1     2      1      2      1      2      1     2 RNAi duplex #
PKCδ
β-actin
PKCε
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Table III.2 Reproducibility of gene expression analyses. There is a concordance of 96% 
between two independent microarray experiments for genes regulated at 4 h after PMA 
treatment. (N.R. = Not Represented).
1s t A RRA Y 2nd A RRA Y
1 M M P10 10.2 10.5
2 DUSP5 9.9 7.8
3 PHL DA 1 9.9 10.3
4 C C L 2 9.8 11.0
5 IL 8 9.8 10.3
6 EDN1 9.0 9.1
7 M A FF 8.8 7.3
8 EM P1 8.8 8.7
9 M M P1 8.6 10.8
10 IT GA 2 8.6 7.8
11 EGR1 8.5 4.7
12 M ET 8.3 9.0
13 C 6o r f145 8.1 8.0
14 T NFA IP3 7.9 8.1
15 BIRC 3 7.8 7.4
16 RSA D2 7.8 6.3
17 SYT L 2 7.7 7.3
18 C 8o r f4 7.6 6.3
19 L IPG 7.5 8.7
20 KRT 34 7.4 7.7
21 SERPINB2 7.4 8.4
22 C 3o r f52 7.2 8.5
23 M M P12 7.1 8.2
24 GA DD45B 7.0 7.6
25 HM OX1 7.0 4.6
26 GBP1 6.9 7.0
27 T NFA IP3 6.9 7.8
28 IGF2BP2 6.8 7.4
29 HEG1 6.8 7.1
30 SFN 6.8 6.8
31 C C L 20 6.8 8.8
32 C YR61 6.7 7.3
33 T UBB6 6.7 6.0
34 T NF 6.6 7.6
35 L EPREL 1 6.6 6.9
36 KRT 20 6.5 3.0
37 PGBD5 6.5 7.1
38 C L DN1 6.5 7.6
39 FHL 2 6.5 7.5
40 A RL 14 6.5 6.7
41 GL IPR1 6.4 6.7
42 PL EKHC 1 6.4 N.R.
43 C 6o r f148 6.4 N.R.
44 BC L 2A 1 6.3 7.9
45 PL A C 8 6.3 5.9
46 T NFRSF12A 6.3 6.0
47 C A C NA 1G 6.2 7.1
48 KL F4 6.2 6.5
49 UL BP2 6.2 5.1
50 EDN2 6.2 7.2
Gene s y mbol
log2Rat (PMA  v s .V eh)
Up-regulated genes Down-regulated genes
1s t A RRA Y 2nd A RRA Y
1 TXNIP -6.9 -6.8
2 PIK3R1 -4.7 -5.4
3 KLK2 -4.7 -5.6
4 SPRY1 -4.6 -5.9
5 PSRC1 -4.6 -5.3
6 TRIM 48 -4.5 -4.3
7 ADRB2 -4.4 -6.9
8 DKFZP434P211 -4.3 -5.2
9 B3GNT1 -4.2 -4.5
10 RAB3A -4.2 -3.4
11 GATA2 -4.0 -3.6
12 SESN1 -4.0 -4.6
13 RIN2 -3.9 -3.1
14 HOXC6 -3.8 -4.3
15 RAB36 -3.7 -3.2
16 SLC25A12 -3.5 -3.8
17 PTGFR -3.5 -3.5
18 SLITRK3 -3.5 -4.4
19 C8or f51 -3.4 -4.4
20 FZD4 -3.4 -3.2
21 ASB13 -3.4 -3.6
22 FRY -3.3 -2.3
23 SM AD6 -3.3 -4.4
24 RPGRIP1L -3.3 -2.2
25 TSC22D3 -3.3 -3.7
26 POLG2 -3.3 -2.6
27 RASL11B -3.3 -4.4
28 SUOX -3.3 -3.0
29 ZNF692 -3.3 -3.1
30 THNSL1 -3.2 -2.4
31 AKAP1 -3.2 -3.1
32 HSPA1A /1B -3.2 -2.5
33 F5 -3.2 -1.1
34 ATAD4 -3.2 -3.4
35 PM S1 -3.1 -2.7
36 ATF7IP -3.1 -3.5
37 V IPR1 -3.1 -3.4
38 TTK -3.1 -2.6
39 SALL2 -3.0 -3.2
40 ZM YM 3 -3.0 -3.2
41 NR2F2 -3.0 -2.8
42 GPRIN2 -2.9 -3.2
43 WNT5A -2.9 -3.1
44 KIF20A -2.9 -4.2
45 GSPT2 -2.9 -2.5
46 KIAA0984 -2.9 N.R.
47 PPP1R3D -2.9 -3.1
48 DFFB -2.9 -3.6
49 SUHW4 -2.9 N.R.
50 LGR4 -2.9 -3.9
log2Rat (PMA  vs . V eh)
Gene Symbol
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III.2.6 Principal component analysis 
A first estimate of the variability in gene expression across the whole genome 
can be obtained by prinicipal component analysis (PCA), in which the global variation 
in gene expression among all samples is analyzed. Using this approach, profound 
changes in PMA-treated samples were observed when compared to vehicle-treated 
LNCaP cells. Importantly, comparison of PCA for samples transfected with either 
control RNAi or PKC isoform-specific RNAi revealed that PKCδ-depleted samples 
were positioned away from the rest, suggesting a high number of genes specifically 
regulated by this isoform in response to PMA (Fig. III.16). 
Figure III.16 Principal component analysis (PCA). PCA represents the global variation in 
three dimensions among all of the samples transfected with either control RNAi or PKC 
isoform-specific RNAi and treated with either vehicle or PMA. Plots are derived from 
expression values for all genes on the microarray. PKCδ-depleted and PMA-treated samples 
are located at unique positions, which indicates a higher number of genes specifically 
regulated by PKCδ.
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III.2.7 PKCδ and PKCε have major, but opposing, roles in gene expression
The next goal was to determine whether PKC isozymes have the ability to 
selectively regulate gene expression. PKC isozyme-specific genes were defined as 
those which displayed ? 1.5-fold change in expression upon depletion of one PKC 
with changes < 1.5-fold upon depletion of the other two PKCs. This analysis revealed 
300 and 439 genes regulated by PKCs under normal growth conditions (vehicle) and 
in response to PMA, respectively. Out of these, 215 (vehicle) and 302 (PMA) genes 
were found to be regulated by one specific PKC isozyme, resulting in well-defined 
isozyme-specific patterns. Surprisingly, the most represented patterns were those for 
isozyme-specific gene regulation by PKCδ and PKCε. Even more, PKCδ was 
primarily involved in the control of PMA-regulated genes, while PKCε primarily 
regulated gene expression in the absence of PMA (Fig. III.17). On the other hand, 
PKCα showed little contribution to specific regulated genes, either in the presence or 
absence of PMA. 
Figure III.17 PKC-isozyme-specific changes in transcription 4 h after PMA treatment 
assign major but opposing roles to PKCδ and PKCε. Comparative analysis in which the 
fold-change PMA/vehicle for one PKC isoform is ? 1.5-fold upon knockdown of this isoform 
revealed that 67% of all PKC-isozyme-regulated genes in the vehicle-treated group are 
controlled exclusively by PKCε whereas 45% of all PKC-regulated genes in response to PMA 
are solely controlled by PKCδ. The total number of genes found to be regulated by PKC 
isozymes was set to 100%.
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11%
2.3%
8.3%
11%
19.3%
6.7%
41.4%
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PKCα PKCδ
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PMA
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Furthermore, analysis of up- and down-regulated genes separately under 
either vehicle- or PMA-treated conditions revealed that knockdown of PKCε mostly 
up-regulated gene expression (46.8% vehicle and 36.1% PMA) (Fig. III.18A), 
suggesting that PKCε primarily reduces gene expression. In contrast, knockdown of 
PKCδ led predominantly to down-regulation of genes (52% vehicle and 63% PMA) 
(Fig. III.18B), arguing for a role of PKCδ in the induction of gene expression. These 
results indicate a major role for PKCε as a negative regulator and PKCδ as a positive 
regulator of transcription.
A
B
Figure III.18 PKC isoform-specific regulation of basal gene expression and after PMA 
treatment. Comparative analysis in which the fold change PMA/vehicle for one PKC isoform 
is ? 1.5-fold (the fold change PMA/vehicle for the other two PKC isozymes is < 1.5-fold 
variation with respect to the control). Panel A. Analysis of up- and down-regulated genes 
separately under vehicle conditions. Basal expression knockdown of PKCε up-regulates 47% 
of all genes up-regulated by PKCs whereas knockdown of PKCδ down-regulates 52% of the 
genes down-regulated by all PKCs. Panel B. In response to PMA 36% of all PKC-regulated 
genes are up-regulated after knockdown of PKCε and 63% are down-regulated after 
knockdown of PKCδ.
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III.2.8 PKCδ as a master regulator of transcription
Next, the analysis was focused on genes that changed significantly upon 
PMA treatment in the presence of all PKC isozymes but had a significantly 
decreased fold change in response to PMA when PKC isozymes were silenced. The 
stringency for determining if a gene was specifically regulated by one particular PKC 
isozyme was increased by including only genes that had a ? 1.5-fold change in 
expression for one isoform knockdown and < 1.25-fold change in the two other 
isoform knockdowns when compared to samples treated with control siRNA and 
PMA. Using these criteria, 75 genes could be identified to be regulated specifically by 
PKCδ, whereas PKCα and PKCε had negligible impact on gene expression (0 and 4 
specific genes, respectively) (Table III.3). Altogether, these results argue for a 
prominent role for PKCδ in the transcriptional control of PMA-mediated responses. 
On the other hand, analysis of genes that lost basal expression by a selective PKC 
RNAi indicated that although PKCδ was the major player, PKCε had a stronger role 
in basal transcription of genes in LNCaP cells (Table III.4).
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Table III.3 PKCδ-specific regulated genes. Applying stringent filters (reduction of PMA-
induced fold change ? 1.5-fold upon knockdown of one PKC isozyme and < 1.25-fold upon 
knockdown of the two remaining PKC isozymes), 75 genes specific for PKCδ are identified. 
F o ld  c h a n g e  (P M A  v s . v e h ic le )
G e n e  S y m b o l c o n t r o l  s iR N A s iR N A  P K C  a lp h a s iR N A  P K C  d e lta s iR N A  P K C  e p s ilo n
C C L 2 0 4 3 1 .9 7 4 4 5 .3 5 6 2 0 5 .7 7 8 3 7 1 .2 1 7
L IP G 4 1 2 .0 6 4 3 8 0 .9 1 3 1 3 8 .7 4 4 3 4 8 .0 3 1
C 3 o r f5 2 3 5 2 .2 2 1 3 4 9 .8 0 8 1 4 0 .4 0 1 3 0 2 .3 8 6
S E R P IN B 2 3 4 7 .5 6 8 2 7 7 .5 0 7 6 9 .0 8 5 2 2 8 0 .9 3 9
M M P 1 2 2 8 9 .5 4 9 2 6 5 .5 9 9 1 0 0 .9 4 4 2 8 5 .6
K IA A 1 1 9 9 2 7 9 .8 2 9 2 6 8 .3 9 4 8 4 .5 4 1 8 2 2 2 .6 9 4
B C L 2 A 1 2 3 1 .6 8 7 2 6 1 .5 5 9 4 1 .0 6 7 2 2 3 1 .0 2 3
L B H 2 2 9 .9 1 1 1 8 1 .1 8 9 6 6 .1 0 4 1 8 0 .4 0 8
F O S L 1 1 7 7 .4 6 6 1 9 7 .1 2 1 5 8 .8 8 2 5 1 6 6 .6 1 4
K H D C 1  / / /  R P 1 1 -2 5 7 K 9 .7 1 7 3 .4 9 1 1 8 5 .2 4 2 5 9 .6 9 1 1 5 0 .3 9
IL 2 R G 1 5 0 .1 7 9 1 3 2 .1 6 6 5 8 .1 7 2 7 1 4 2 .7 0 4
N A V 2 1 4 1 .6 8 5 1 2 4 .7 7 4 5 7 .2 5 0 3 1 3 7 .4 2 5
C 6 o r f5 4 1 4 0 .3 3 3 1 4 8 .9 5 3 6 4 .4 4 2 1 1 2 6 .3 3
G E M 1 3 9 .1 1 6 1 0 4 .4 5 8 2 5 .2 0 8 1 1 5 4 .4 6 9
K IA A 1 4 6 2 1 3 4 .6 4 9 1 3 8 .6 8 2 4 2 .0 5 7 7 1 3 1 .9 8 7
K L F 6 1 1 8 .6 5 1 0 5 .5 9 4 4 9 .7 2 8 6 8 9 .5 5 4 4
Z E B 1 1 1 1 .1 1 3 9 6 .0 6 9 1 5 2 .8 6 6 7 9 8 .1 7 4 6
A L O X E 3 8 0 .6 2 7 1 9 1 .4 7 5 4 3 9 .8 2 1 7 8 2 .6 6 7 9
A R ID 3 B 6 9 .8 0 1 6 5 4 .2 5 8 6 2 2 .8 9 1 9 5 9 .2 6 6 2
G P R C 5 A 6 5 .3 5 4 8 7 8 .6 6 9 6 1 1 .7 4 9 4 5 2 .1 4 3 6
T R A F 1 5 2 .8 5 9 1 5 8 .7 9 0 9 1 5 .2 6 3 9 4 6 .3 4
L IF 4 9 .6 3 7 4 5 1 .2 9 1 7 .5 7 2 7 5 1 .5 5 5 2
L A M B 3 4 8 .2 1 9 6 5 7 .5 2 1 4 2 3 .6 0 5 2 5 0 .7 0 4 7
P P P 1 R 1 5 A 4 4 .8 1 5 6 3 7 .2 7 1 2 1 2 .9 5 9 1 3 9 .9 8 2 5
F B N 1 2 6 .8 3 6 5 2 6 .0 9 8 5 1 0 .4 5 9 5 3 0 .4 6 1
L O C 1 0 0 1 2 8 4 4 3  / / /  M A S T 4 2 4 .1 4 5 7 2 3 .4 6 6 4 5 .9 7 7 6 4 1 9 .0 7 1 2
S P H K 1 2 2 .7 1 7 7 2 8 .0 2 7 5 3 .2 9 8 6 1 2 4 .7 4 8 9
C A M S A P 1 1 9 .6 0 9 6 1 7 .2 4 7 3 9 .7 9 6 2 6 1 7 .7 9 5 3
IC O S L G 1 9 .5 8 6 4 1 8 .9 4 5 7 9 .2 8 6 9 1 8 .0 1 3 6
C C R N 4 L 1 8 .3 2 8 4 1 5 .3 0 4 2 6 .7 2 4 9 6 1 8 .2 6 7
L D L R 1 8 .1 3 5 8 1 3 .6 8 8 5 8 .3 0 1 2 3 1 5 .2 6 9 6
E T S 2 1 7 .6 9 6 8 1 5 .9 4 8 4 5 .2 8 1 1 1 6 .0 5 3 7
G P R 8 7 1 5 .9 5 5 7 1 2 .7 2 6 5 3 .6 5 2 5 1 5 .6 9 1 4
C D 4 1 1 .4 3 7 3 9 .5 9 8 8 6 3 .3 0 8 5 9 .4 1 0 9 4
P D L IM 7 1 0 .7 2 3 8 .6 1 0 3 1 5 .1 7 4 2 1 0 .3 3 3
F E M 1 B 9 .8 6 6 1 4 9 .7 1 1 1 8 3 .9 0 2 1 4 8 .5 3 5 2 4
U G C G 6 .9 7 5 1 5 5 .3 7 1 7 8 3 .4 7 9 2 6 5 .3 6 8 7 8
R Y B P 6 .9 0 6 3 5 6 .2 3 9 1 9 3 .2 6 5 5 8 5 .8 9 7 9 7
L Y S T 6 .7 3 7 1 1 5 .8 1 8 8 8 3 .2 6 8 9 9 5 .4 3 8 2 4
IT P R 3 6 .4 6 6 3 2 6 .4 6 8 1 2 3 .2 1 3 2 5 .1 9 4 1 4
U S P 3 6 5 .8 5 8 5 1 6 .4 9 4 5 7 2 .4 9 3 9 3 5 .2 2 1 4 2
O A S 1 5 .7 7 9 7 5 4 .9 2 8 5 4 2 .6 3 2 9 6 4 .3 9 3 0 2
A P O B E C 3 A 5 .3 8 2 9 7 6 .2 7 1 0 5 1 .4 8 1 7 6 5 .8 7 3 0 4
S L C 2 2 A 1 5 .0 8 5 1 4 6 .1 1 8 8 4 1 .6 1 6 3 5 3 .8 9 9 6 1
P L A G L 2 4 .9 5 3 1 2 4 .9 1 8 1 9 2 .3 1 1 0 5 4 .3 4 9 1 8
C D K N 2 A 4 .4 5 7 6 3 4 .2 7 0 4 8 1 .9 4 7 7 5 3 .4 8 4 9 9
D E N N D 3 4 .4 5 1 0 7 5 .5 6 1 4 8 1 .3 0 4 7 1 3 .4 1 9 6 5
IL 1 R N 3 .8 0 7 2 4 3 .7 7 0 6 7 1 .0 3 9 1 3 .4 1 1 2 9
T T C 9 3 .7 3 4 8 1 4 .4 4 4 7 1 1 .7 8 0 4 5 4 .0 8 9 1 4
K IA A 0 9 9 9 3 .7 0 9 3 2 2 .9 5 4 6 1 .5 6 6 9 7 3 .1 1 0 1 2
C T S B 3 .4 1 3 5 4 3 .2 0 3 9 4 1 .3 6 1 9 5 2 .6 1 3 1 1
T R P C 1 3 .3 6 8 4 2 2 .8 6 2 2 9 1 .2 4 4 5 7 3 .6 7 0 3 2
M Y O 9 B 3 .2 0 2 7 4 3 .1 4 4 3 7 1 .2 0 8 5 6 2 .6 6 7 2 6
S O C S 1 3 .0 6 9 6 5 2 .6 5 0 8 6 1 .3 1 1 1 2 3 .3 7 3 8 5
T P B G 3 .0 3 7 2 6 3 .7 8 8 2 1 .2 6 5 9 5 3 .4 5 2 8 1
S L C 1 5 A 1 2 .7 6 1 2 8 2 .4 2 3 8 2 1 .2 8 5 7 3 .2 8 6 6 9
T N F R S F 1 1 B 2 .1 7 1 0 7 1 .9 4 8 9 4 1 .0 2 2 7 6 1 .8 2 6 9 6
M R P S 1 1 -2 .0 7 0 1 9 -1 .6 3 1 4 1 1 .0 1 6 0 7 -1 .8 8 6 4 9
E R C C 6 L -2 .5 0 1 1 1 -2 .2 1 8 7 7 -1 .1 3 3 2 2 -1 .9 7 4 4
R IC S -2 .7 8 4 5 2 -2 .3 2 5 8 2 -1 .1 0 0 2 2 -2 .7 6 9 6 1
F Z D 1 -3 .6 7 2 8 6 -3 .4 8 9 4 5 -1 .7 5 8 8 5 -3 .3 0 0 2
S E T B P 1 -3 .9 2 5 9 9 -3 .7 8 8 9 -1 .8 8 6 8 3 -3 .8 2 4 2 7
H J U R P -4 .3 6 1 6 8 -3 .5 1 1 8 -2 .1 6 6 8 5 -3 .7 3 2 1 9
A D A M 7 -4 .6 1 8 1 7 -3 .6 1 8 1 3 -1 .7 4 4 4 4 -4 .6 6 5 6 7
P A L M D -6 .6 4 7 0 9 -5 .9 5 5 8 1 -2 .9 6 0 2 5 -7 .3 7 1 0 1
E P O R -8 .1 7 6 3 1 -7 .0 8 5 5 2 -3 .2 3 7 7 7 -6 .7 5 0 3 9
P P P 1 R 3 D -8 .5 8 9 3 1 -9 .6 1 7 9 1 -4 .1 3 0 7 -9 .6 6 5 4
K IF 2 C -9 .3 6 1 9 9 -8 .4 7 4 7 4 -4 .4 5 1 5 4 -7 .6 6 1 6 6
G R H L 2 -1 1 .9 1 3 8 -1 2 .6 5 9 -5 .7 3 5 6 2 -9 .5 1 3 7 8
T R IM 4 8 -2 0 .0 4 8 4 -2 1 .2 9 5 6 -6 .8 1 4 8 1 -1 5 .5 3 3 8
S L IT R K 3 -2 0 .4 5 7 9 -1 9 .6 8 8 6 -6 .9 6 5 3 4 -1 8 .1 7 5 6
S M A D 6 -2 0 .6 5 2 2 -1 7 .6 4 5 7 -8 .3 4 8 5 6 -1 7 .7 7 0 5
C 8 o r f5 1 -2 1 .3 2 3 3 -2 4 .3 3 2 2 -8 .4 8 8 3 7 -2 2 .1 6 5 5
O S R 2 -2 6 .5 4 4 3 -2 1 .5 8 3 4 -4 .6 3 6 -2 0 .4 4 0 7
S P R Y 1 -6 0 .0 9 9 4 -5 3 .9 6 3 6 -1 7 .4 9 4 8 -5 9 .9 4 2 9
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Table III.4 PKCε-specific regulated genes. Applying stringent filters (reduction of PMA 
induced fold change ? 1.5-fold upon knockdown of one PKC isozyme and < 1.25-fold upon 
knockdown of the two remaining PKC isozymes), 4 genes specific for PKCε are identified. 
III.2.9 Validation of microarray studies by RT-PCR
In order to validate the results obtained in the microarray studies, a subset of 
genes specifically regulated by PKCδ (BCL2A1, FOSL1, TRAF1, SERPINB2, SPHK1, 
PPP1R15A) was selected for their well known and important functions, such as 
apoptosis signaling or proliferation, as outlined below:
BCL2A1 encodes a member of the BCL-2 protein family. The proteins of this 
family form hetero- or homodimers. They act as anti- and pro-apoptotic regulators 
that are involved in a wide variety of cellular activities, including tumorigenesis. This 
gene is a direct transcription target of NF-κB in response to inflammatory mediators, 
and it is up-regulated by different extracellular signals, such as phorbol ester and the 
inflammatory cytokines TNFα and IL-1, which suggests a cytoprotective function 
essential for cell survival [101].
FOSL1 belongs to the Fos gene family which consists of 4 members (FOS, 
FOSB, FOSL1, and FOSL2). These genes encode proteins which are components of 
the transcription factor complex AP-1. FOS proteins have been implicated in cell 
proliferation, differentiation, and transformation [102, 103].
Tumor necrosis factor receptor-associated factors (TRAFs) are cytoplasmic 
adapter proteins that link a wide variety of cell surface receptors to the apoptotic 
signaling cascade [104]. Specifically, TRAF1 has been implicated in the modulation 
F o ld  c h a n g e  ( P M A  v s .  v e h ic le )
G e n e  S y m b o l c o n t r o l  s iR N A s iR N A  P K C  a lp h a s iR N A  P K C  d e l t a s iR N A  P K C  e p s i lo n
B IR C 3 1 7 1 .1 1 8 1 4 7 .8 2 8 2 0 3 .2 5 4 7 5 .6 5 1 6
C Y R 6 1 1 5 7 .8 3 4 1 8 8 .2 9 9 1 2 5 .9 1 1 7 8 .7 1 0 2
R G S 2 2 3 .6 2 1 1 8 .0 6 7 2 4 .0 4 1 5 9 .0 3 5 9 2
A M IG O 2 - 2 .7 1 0 8 - 2 .2 9 5 3 6 - 2 .0 9 7 3 6 1 .0 9 3 1 3
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of TNFα signaling and subsequent apoptosis, where it can exert both pro- and 
antiapoptotic effects [105].
SERPINB2, also known as Plasminogen activator inhibitor-2 (PAI-2) regulates 
proliferation and differentiation of monocytes [106]. Intracellular PAI-2 is an important 
factor in regulating cell death in TNFα-mediated inflammatory processes through 
inhibition of a proteinase involved in TNFα-induced apoptosis [107].
Sphingosine kinase (SPHK) is the enzyme that catalyzes the phosphorylation 
of sphingosine to sphingosine-1-phosphate (SPP), which is a lipid messenger with 
intracellular and extracellular functions, including proliferation and survival [108].
Protein phosphatase 1, regulatory (inhibitor) subunit 15A (PPP1R15A) is a 
member of a group of genes whose transcript levels are increased following stressful 
growth arrest conditions and treatment with DNA-damaging agents. The induction of 
this gene by ionizing radiation occurs in certain cell lines regardless of p53 status, 
and its protein response is correlated with apoptosis following ionizing radiation [109].
Quantitative RT-PCR was performed using primers specific for the 
aforementioned genes and cDNA transcribed from the RNA that has been initially 
obtained for the global gene expression analysis. There was a remarkable 
agreement between microarray data and qPCR analysis for all selected genes (Fig. 
III.19). This indicated a high degree of reliability of the genome-wide expression 
analysis on the one hand and highlighted the importance of PKCδ for the induction of 
these genes on the other. 
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SPHK1
PPP1R15A
Figure III.19 Validation of microarray studies confirms a high reliability of the genome-
wide expression analysis. GCRMA data of FOSL1, BCL2A1, SERPINB2, TRAF1, SPHK1, 
and PPP1R15A obtained in the microarray study were normalized to GAPDH (left side of 
each panel). Data of the quantitative RT-PCR were normalized to 18S (right side of each 
panel). In order to analyze PKCδ-specific genes two different RNAis for PKCδ were used. For 
control and the PKCα and PKCε isoforms one specific siRNA was used. Fold changes were 
referred to samples transfected with control RNAi and treated with vehicle. Data represent the 
mean ± S.E.M. of three independent experiments, *p<0.05.
III.2.10 Identification of novel genes implicated in PMA-induced and PKCδ-
mediated apoptosis in LNCaP cells 
As described earlier, PKCδ is the primary mediator of PMA-induced apoptosis 
in LNCaP cells. In order to determine the potential involvement of candidate genes in 
this effect, a selective RNAi-mediated knockdown experiment for 4 different PKCδ-
regulated genes (BCL2A1, FOSL1, TRAF1, SERPINB2) was conducted. 
Transfection of the specific ON-TARGET®plus SMARTpool siRNAs into LNCaP cells 
prevented the up-regulation of each corresponding mRNA by PMA (Fig. III.20A). 
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Remarkably, siRNA against either BCL2A1 or FOSL1, but not of SERPINB2 and 
TRAF1, significantly reduced the apoptotic effect of PMA in LNCaP cells (Fig. III.20B). 
A
B
Figure III.20 FOSL1, BCL2A1 and PKCδ play an important role in PMA-induced 
apoptosis in LNCaP cells. Panel A. RNA interference efficiently prevents an increase in 
mRNA levels of PKCδ-dependent genes as measured by quantitative RT-PCR. Data 
represent the mean ± S.E.M. of three independent experiments. Panel B. Percentage of 
apoptotic LNCaP cells was assessed 24 h after treatment with PMA (100 nM) by nuclear 
staining with DAPI. Similar to depletion of PKCδ, reduction of mRNA levels significantly 
reduces the PMA-induced apoptosis for BCL2A1 (B) and FOSL1 (F). Knockdown of 
SERPINB2 (S) and TRAF1 (T) does not significantly decrease PMA-induced apoptosis. Data 
represent the mean ± S.E.M. of three independent experiments, ***p<0.001.
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To minimize the chance of “off-target” effects of RNAi we carried out 
additional experiments using two different RNAi duplexes for FOSL1 and BCL2A1, 
and observed similar results (Fig. III.21A and B).
A
B
Figure III.21 FOSL1 and BCL2A1 mediate PMA-induced apoptosis. LNCaP cells 
transfected with one control RNAi duplex (240 pmol) or two different specific RNAi duplexes 
(240 pmol) for each gene were stimulated with PMA (100 nM). Panel A. RNA interference 
efficiently prevents an increase in mRNA levels of PKCδ-dependent genes. Data represent 
the mean ± S.E.M. of three independent experiments. Panel B. Percentage of apoptotic 
LNCaP cells was assessed 24 h after treatment with PMA (100 nM) by nuclear staining with 
DAPI. Data confirm the results obtained after transfection with SMARTpool RNAi for FOSL1
and BCL2A1. Data represent the mean ± S.E.M. of three independent experiments, *p<0.05 
and ***p<0.001.
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III.2.11 PKCδ-mediated transcriptional regulation is required for etoposide-
induced apoptosis 
To further validate the genes regulated by PKCδ in PMA-induced apoptosis, 
and to further support the concept of PKCδ’s involvement in gene regulation during 
programmed cell death, etoposide was used as a different means to induce 
apoptosis in LNCaP cells (Fig. III.22). Importantly, the involvement of PKCδ in up-
regulation of candidate genes was confirmed in LNCaP cells subjected to etoposide 
treatment. 
Figure III.22 Etoposide induces apoptosis in LNCaP cells. Induction of apoptosis by 
??????????????????????????????????????????????????????5 h after treatment and evaluating 
cells for chromatin fragmentation. Data represent the mean ± S.E.M. of three independent 
experiments.
Interestingly, cells treated with etoposide showed a similar pattern of 
induction of FOSL1, BCL2A1, SERPINB2 and TRAF1 (Fig. III.23). 
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Figure III.23 Etoposide induces mRNA levels of FOSL1, BCL2A1, SERPINB2 and TRAF1
in LNCaP cells. Treatment of LNCaP cells with etoposide for 5 h (400µM) results in the
induction of mRNA levels of FOSL1, BCL2A1, and SERPINB2. Data represent the mean ± 
S.E.M. of three independent experiments.
To evaluate the role of PKCδ in this model, knockdown of PKCδ was 
conducted prior to the induction of apoptosis with etoposide (Fig. III.24A). Reduced 
apoptosis could be observed when cells had been depleted of PKCδ (Fig. III.24B).
This confirms that PKCδ is a strong mediator of etoposide-induced apoptosis in 
LNCaP cells, as described for other cell types [110, 111]. Most importantly, silencing 
of PKCδ blunted mRNA induction of all of the four candidate genes by etoposide. (Fig. 
III.24C). 
A B
PKCδ
β-actin
RNAi C       δ #1    δ #2
PKC
control kd delta 1 kd delta 2
50
100
0R
el
at
iv
e 
ap
o
p
to
si
s 
%
C δ#1RNAi δ#2
PKC
Etoposide
vehicle
* p < 0.05
*
*
R
el
at
iv
e 
ap
o
p
to
si
s 
%
ctr 400µM
Etoposide - +    
25
50
75
0
100
m
R
N
A
 le
ve
l
(f
o
ld
 in
d
u
ct
io
n
)
SERPINB2
ctr 400µM
Etoposide - +    
0.0
2.5
5.0
7.5
TRAF1
m
R
N
A
 le
ve
l
(f
o
ld
 in
d
u
ct
io
n
)
m
R
N
A
 le
ve
l
(f
o
ld
 in
d
u
ct
io
n
)
m
R
N
A
 le
ve
l
(f
o
ld
 in
d
u
ct
io
n
)
III RESULTS 108
C
Figure III.24 FOSL1, BCL2A1, SERPINB2 and TRAF1 are induced by etoposide in a 
PKCδ-dependent manner. Panel A. Western blot analysis shows sufficient knockdown of 
PKCδ. Panel B. Treatment of LNCaP cells transfected with two separate siRNAs for PKCδ
(120 pmol) with etoposide (400 µM) reduces apoptosis. Apoptosis was determined 48 h after 
stimulation with etoposide (400 µM), showing a significant reduction for the samples depleted
of PKCδ. Panel C. Treatment of LNCaP cells with etoposide (400 µM) reveals a significant 
PKCδ dependent induction of FOSL1, BCL2A1, SERPINB2, and TRAF1. The induction of all 
four genes is significantly reduced when PKCδ is silenced. Samples transfected with control 
siRNA and treated with etoposide were arbitrarily set to 100%. Data represent the mean ± 
S.E.M. of three independent experiments, *p<0.05.
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IV DISCUSSION
IV.1 Bryostatin 1 inhibits PMA-induced apoptosis in LNCaP cells
Bryostatin 1, a macrocylic lactone derived from the marine species Bugula 
neritina, has been reported previously to exert anti-proliferative and apoptotic effects 
in numerous cancer cell lines [112-114]. Moreover, it has been used successfully for 
tumor treatment in animal studies [69, 71] and is currently being investigated in 
clinical trials against various solid tumor as well as hematologic malignancies [73, 74, 
76, 77]. However, the effect of bryostatin 1 on prostate cancer cells is unknown. 
Bryostatin 1 is a potent ligand at the C1 domain of PKCs, similar to the phorbol ester 
PMA, which is known to induce apoptosis in the prostate cancer cell line LNCaP. 
Given the described anti-cancer effects of bryostatin 1 on the one hand and the pro-
apoptotic effect of PMA on LNCaP cells on the other, one aim of this study was to
assess the effect of bryostatin 1 on LNCaP prostate cancer cells on its own and 
whether it augments, attenuates or does not affect PMA-induced apoptosis in this cell 
line. 
To validate previous findings, LNCaP cells were first treated with PMA alone. 
Here, PMA increased the rate of apoptosis in a dose-dependent manner. Based on 
this finding, the concentration of PMA used for further experiments was determined 
to be 100 nM. In contrast, bryostatin 1 failed to induce apoptosis at any used 
concentration. More importantly, bryostatin 1 decreased and ultimately blocked PMA-
induced apoptosis in LNCaP cells dose-dependently. Remarkably, the expression 
levels of the anti-apoptotic proteins MCL1, BCL-XL and BCL-2 were not found to be 
altered, suggesting that bryostatin 1 does not act through the induction of de novo
synthesis of these proteins. Also the well-described phosphorylation of p38 and 
dephosphorylation of pAkt by PMA were unaffected by bryostatin 1, indicating that at 
least a subset of PMA-induced effects were still executed. 
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Another well-known effect of PMA is the release of TNFα and other factors 
from LNCaP cells. Therefore, the question whether bryostatin 1 affects the 
composition of the conditioned medium (CM) was addressed. Indeed, whereas CM-
PMA was capable of inducing apoptosis in naïve LNCaP cells, CM-Bryo1 and, more 
importantly, CM-Bryo1+PMA failed to induce apoptosis. As with cells that are directly 
treated with PMA and bryostatin 1, cells that received CM-Bryo1+PMA still exhibited 
phosphorylation of p38, which was maintained over several hours, as well as 
phosphorylation of JNK and dephosphorylation of pAkt. Taken together, these data 
are in favor with the hypothesis that bryostatin 1 prevents PMA from triggering the 
release of pro-apoptotic factors to the CM, while others are still being secreted and 
are capable of triggering a cascade that leads ultimately to the phosphorylation of 
p38 and JNK and dephosphorylation of pAkt, respectively. Although a cytokine array 
did not reveal any obvious difference in the secretion of pro-apoptotic factors, 
probably due to issues of sensitivity [94], a more accurate measurement employing 
ELISA revealed that PMA-induced secretion of TNFα is essentially blunted by 
bryostatin 1. PMA, in turn, depends on the autocrine secretion of this cytokine for 
killing prostate cancer cells [57]. The impaired TNFα secretion by PMA when cells 
are simultaneously treated with bryostatin 1 seems to fully account for the functional 
antagonism. Indeed, adding back this cytokine at similar final concentrations as those 
normally observed in CM-PMA fully restores the apoptotic activity. It is interesting 
that bryostatin 1 promotes apoptosis and TNFα release from leukemia cells [115, 
116], suggesting a strict cell type dependency for the differential killing ability of this 
agent.
Our laboratory established that TNFα release from prostate cancer cells 
induced by PMA is mediated by PKCδ [57]. This paradigm has been recently 
validated in vascular smooth muscle cells [117]. Moreover, it appears that none of 
the other PKC isozymes expressed in LNCaP cells can compensate for the loss of 
IV DISCUSSION 111
PKCδ, as the single knockdown of PKCδ decreased both the rate of apoptosis and 
the release of TNFα followed by treatment with PMA. These findings highlight PKCδ
to be the most critical PKC isozyme in mediating PMA-induced apoptosis in LNCaP 
cells. It is a well known phenomenon that PKCδ needs to be translocated to the 
plasma membrane in a fashion as depicted in Fig. I.7. This raised the question 
whether translocation to the plasma membrane and subsequent activation of PKCδ is 
impaired upon treatment with bryostatin 1. As a matter of fact, bryostatin 1 selectively 
translocated PKCδ, but not PKCα or PKCε, to the nuclear membrane and importantly, 
almost completely blocked PMA-induced translocation of PKCδ to the plasma 
membrane. One possible explanation by which this prevents the release of TNFα is 
the necessity of TACE/ADAM17 phosphorylation (TNFα converting enzyme). As 
TACE is a membrane bound enzyme [118], phosphorylation could either happen 
directly through PKCδ or by PKC downstream effector kinases, as previously 
reported [119]. Either way, the data presented here demonstrate that relocalization of
PKCδ to the plasma membrane of LNCaP cells is required for promoting an apoptotic 
response. Remarkably, expression of a membrane (myr) targeted PKCδ in LNCaP 
cells is sufficient to promote apoptosis, and conversely limiting the access of PKCδ to 
the plasma membrane prevents the apoptotic effect of PMA.
The ability of bryostatin 1 to differentially translocate PKC isozymes is a well-
documented phenomenon. Early studies using GFP-tagged PKCs revealed 
distinctive patterns of translocation for PKC isozymes in living cells in response to 
different PKC activators and other stimuli. In this regard, it is striking that ligands that 
are all capable of binding with high affinity to the C1 domains confer such distinct 
patterns of PKC relocalization, a paradox that is particularly observed for PKCδ [82, 
120]. The pattern of translocation of PKCδ in LNCaP cells resembles that observed 
originally in CHO cells, in which bryostatin 1 translocates PKCδ predominantly to the 
nuclear membrane [82]. Our studies revealed that in LNCaP cells bryostatin 1 
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prevents PKCδ translocation to the plasma membrane by PMA while still allowing for 
nuclear membrane relocalization of PKCδ, and without significantly affecting 
translocation of PKCα or PKCε to the plasma membrane. The circumstance that 
some of the PMA-induced effects were still observed in LNCaP cells, i.e.
phosphorylation of p38 and JNK as well as dephosphorylation of pAkt, is in line with 
the observation that bryostatin 1 specifically affects PKCδ activity, but not the 
function of PKCα or PKCε. As reported previously, PKCα significantly contributes to 
the phosphorylation of p38 and the dephosphorylation of pAkt [57] (see Fig. I.9). On 
the other hand, these findings indicate that activation of p38 and inactivation of Akt 
may be required for apoptosis in LNCaP cells, but these events are not sufficient for 
the induction of apoptosis on their own. 
The results reported here strongly support the hypothesis that bryostatin 1
exerts its anti-apoptotic effects in LNCaP cells through a functional antagonism 
driven by mislocalization of PKCδ, ultimately restraining the access of this kinase to 
plasma membrane substrates. The basis for the differential subcellular translocation 
by PMA and bryostatin 1 remains to be determined. The interactions between the C1 
domain in PKCs, C1 domain ligands, and the lipid bilayers are complex and not 
totally understood. 
Previous studies conducted by Peter Blumberg and co-workers established that a 
key determinant for conferring ligand selectivity for PKC translocation is lipophilicity 
[120]. It is tempting to speculate that the differential relocalization pattern of PKCδ by
PMA and bryostatin 1 is due to distinct hydrophobic interactions with the lipid bilayer.
Binding of a C1 ligand into a hydrophilic cleft at the C1 domain leads to an overall 
more hydrophobic composition of this domain, thus allowing for lipophilic interactions 
with the plasma membrane and the subsequent insertion of this domain into the lipid 
bilayer. Additional interactions between the side-chains of the ligand and the 
membrane may be therefore key for dictating intracellular selectivity through specific 
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association with membrane components. Another mechanism by which localization 
of PKCδ may be differentially regulated is that binding of different ligands confers 
differential interaction between PKCδ and various interacting proteins, which then 
direct the kinase to distinct localizations within the cell. 
Taken together, the data presented here indicate that bryostatin 1 does not 
induce apoptosis in the prostate cancer cell line LNCaP and impairs the PKCδ-
dependent release of TNFα, thereby attenuating the apoptotic effect of PMA. As 
several chemotherapeutic agents depend on PKCδ to promote prostate cancer cell 
death [121], these data suggest that bryostatin 1 may have limited effectiveness in 
combination therapies with certain anti-cancer agents for prostate cancer treatment.
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IV.2 PKC regulation of gene expression
Given the overall importance of PKC isozymes in triggering PMA-induced 
apoptosis, the question whether PKC activation in general and isozyme-specific 
activation in particular has an impact on transcriptional regulation in LNCaP cells in 
the context of PMA-induced apoptosis was addressed. Treatment of LNCaP cells 
with the protein synthesis inhibitor Chx prior to the application of PMA resulted in a 
signifcantly reduced apoptotic effect of PMA, suggesting that triggering the apoptotic 
process requires de novo synthesis of proteins and therefore, presumably, of mRNA 
as well. In our study we focused on three different aspects: (1) The time-course of 
changes in global gene expression after PMA treatment; (2) Classification of the 
response to PMA exposure in biological functions (Gene Ontologies) and (3) 
Functional relevance of PKC isozymes on gene expression in LNCaP cells. 
By conducting a longitudinal study observing changes of global gene 
expression over 24 h after exposure to PMA, it was possible to determine that major 
changes take place initially after drug exposure and reach their peak within 4 h. At 
later stages, alterations in gene expression can be observed only in a relatively small 
proportion of genes. Investigating changes in gene expression in relation to PMA-
induced apoptosis at 4 h allowed for the maximum of altered genes to be included 
and reduced the evaluation of secondary regulated genes, which are likely to be 
included at later stages. Of the genes regulated in this time frame most are related to 
signal transduction and modulation of transcription, indicating profound changes in 
essential cell fate determinants. In conclusion, genome-wide expression analysis in 
combination with exposure to a specific drug can be useful for further analysis of 
specific signaling pathways in response to this particular drug.
To determine the role of PKC isozyme-specific functions, knockdown of PKCα, 
PKCδ or PKCε was successfully achieved using RNAi and subsequent gene 
expression analysis was carried out in response to PMA. Although stable knockdown 
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is desirable, it is not feasible in this model as LNCaP cells transition from an 
androgen-dependent state to an androgen-independent state upon long-term 
culturing. This, in turn, affects the response to PMA [122, 123]. The robustness of the 
microarray experiments is underscored by the high similarity between genes 
regulated by PMA after 4 h in the longitudinal microarray study and the genes 
regulated by PMA in the sample using control siRNA. A rough estimate of variability 
in gene expression across the whole genome was obtained by principal component 
analysis (PCA), which revealed profound changes between PMA- and vehicle-treated 
LNCaP cells. Importantly, comparison of PCA for samples transfected with either 
control RNAi or PKC isoform-specific RNAi revealed that PKCδ-depleted samples 
were differentially positioned, suggesting a high number of genes specifically 
regulated by this isoform in the context of PMA induced apoptosis. Most interestingly, 
distinct, stimulus-dependent roles for PKC isozymes were identified. In cells not 
exposed to PMA (only growing in normal medium containing FBS), knockdown of 
PKCε evoked the largest change in gene expression. Moreover, depletion of this 
isoform resulted predominantly in up-regulation, rather than down-regulation of genes. 
These data suggest that PKCε may function in favor of a normal, proliferative state in 
line with previous descriptions as a mitogenic and pro-survival kinase. PKCε has 
been linked to prostate cancer progression in particular [10, 96, 124-127] and has 
been assigned to oncogenic functions in a broad variety of tissues [128]. In contrast 
to these observations, exposure to PMA, which is followed by apoptosis in LNCaP 
cells, is accompanied by changes in gene expression that are primarily mediated by 
PKCδ. Interestingly, and in opposite to PKCε, PKCδ alters the gene expression levels 
predominantly by up-regulation. Taken together, these findings suggest that the pro-
survival kinase PKCε may act as a more repressing kinase, as depletion of PKCε
from LNCaP cells resulted in up-regulation of gene expression. In contrast, the pro-
apoptotic kinase PKCδ predominantly controls pathways that lead to the activation of 
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gene transcription. Moreover, our results suggest that PKCε may be more relevant in 
controlling gene expression under “physiological” conditions whereas PKCδ may
have relevant roles in response to phorbol ester stimulation.
To narrow the number of genes regulated by PKC isozymes, more stringent 
criteria were applied (reduction of PMA-induced fold change ? 1.5-fold upon 
knockdown of one PKC isozyme and < 1.25-fold upon knockdown of the two 
remaining PKC isozymes). This analysis revealed that 75 PMA-regulated genes were 
specifically induced by PKCδ, whereas PKCα and PKCε had negligible impact on 
gene expression. This finding confirms the results obtained in the principal 
component analysis and argues for PKCδ as a master regulator of the genome in the 
response to phorbol ester stimulation. 
To further validate the data generated in the microarray experiments, 
quantitative RT-PCR (qRT-PCR) was performed on PKCδ-regulated genes (BCL2A1, 
FOSL1, TRAF1, SERPINB2, SPHK1, PPP1R15A), which were chosen upon their 
already known involvement in the control of apoptosis. The remarkable agreement 
between microarray data and qRT-PCR analysis for all selected genes is indicative of
a high degree of accuracy and reliability of the genome-wide expression analysis.
Given the importance of selected PKCδ-regulated genes in apoptosis, it was 
of interest to evaluate their functional relevance in PMA-induced apoptosis in LNCaP 
cells. To achieve this goal, LNCaP cells had to be transfected with pooled siRNA 
prior to the treatment with PMA, so that the interfering RNA was already present at 
the onset of gene transcription, thus preventing an increase of the mRNA. Indeed, 
this approach proved to be successful, as mRNA levels of genes of interest could be 
blunted in the presence of siRNA and PMA. Knockdown of some genes regulated by 
PKCδ, but not all, was able to reduce the apoptotic response of PMA. The results 
showed that none of the single knockdowns prevented PMA-induced apoptosis as 
efficiently as the depletion of PKCδ. This observation may have two reasons. First, 
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PKCδ signaling results in the transcription of multiple genes that synergistically act on 
the activation of apoptosis, and second, phosphorylation of target proteins by PKCδ
may lead to other pro-apoptotic functions than transcriptional regulation. However, 
these two processes might not be independent from each other. As already 
demonstrated in this study, PKCδ is critical for the release of TNFα, which leads to 
the assembly of the DISC and subsequently to caspase activation on the one hand. 
On the other hand, binding of TNFα to its receptor can lead to the activation of 
transcription, in part through the NFκB pathway [129]. Indeed, SERPINB2, FOSL1
and BCL2A1 have been described to undergo transcriptional activation in response 
to TNFα treatment, and BCL2A1 is a known target of the NFκB pathway [101, 102, 
130].
Since above-mentioned knockdown studies had been conducted with pooled 
siRNA targeting multiple sequences of the same mRNA, there was a possibility that 
off-target effects might have occurred. To reduce the potential impact of off target 
effects of pooled siRNA, knockdown of FOSL1 and BCL2A1 was also performed 
using two separate siRNAs. Again, transfection of a single siRNA prevented gene 
induction and apoptosis by PMA, suggesting specific involvement of these genes. 
The fact that etoposide-induced apoptosis requires PKCδ as well as the 
induction of PKCδ target genes in a similar manner as it is required for PMA-induced 
apoptosis serves as a proof of concept and suggests that a general involvement of 
PKCδ upstream of the pro-apoptotic signaling is mandatory for the induction of 
apoptosis [131]. In addition, the requirement of PKCδ in etoposide-induced apoptosis 
indicates a stimulus-independent function for PKCδ as a regulator of apoptosis. 
Although there is some evidence that BCL2A1 may be influenced by the PLC-DAG-
PKC signaling axis [132], the involvement of this gene in the positive regulation of 
apoptosis is a surprising result as the majority of reports demonstrate an anti-
apoptotic function for BCL2A1 [132, 133]. FOSL1 is a member of the AP-1 
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transcription complex and is also known to support growth and survival in 
transformed cells [134]. In addition, knockdown of FOSL1 induces apoptosis in a 
variety of cancer cells [135]. However, overexpression of FOSL1 in glioblastoma cells 
induces apoptosis [136] and increases the sensitivity against erlotinib, an inhibitor of 
the EGFR signaling pathway [137]. This and the results shown here indicate that 
biological functions of certain gene products may vary dependent on the cellular 
context rather than on the apoptotic stimulus, as shown by concomitant increase of 
apoptosis and up-regulation of BCL2A1 and FOSL1 by both PKCδ-dependent 
apoptosis-inducing agents, PMA and etoposide.
Taken together, this is the first comprehensive evaluation of transcriptional
dynamics of LNCaP cells in response to the PKC activator PMA. In addition, 
genome-wide expression analysis revealed distinct roles for PKC isozymes during 
normal growth/proliferation and apoptosis and how signaling molecules impact the 
regulation of transcription in a genome-wide scale.
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V SUMMARY
Prostate cancer is the leading cause of cancer related deaths in men in the
United States and is characterized by altered expression patterns of PKC isozymes, 
among other genetic and epigenetic disturbances. PKCs are involved in multiple 
cellular processes including cell survival, proliferation, apoptosis and differentiation.
The current concept is that the effect is isozyme-, cell type- and stimulus-dependent. 
Activation of PKCs occurs through binding of ligands to their C1 domain and can be 
of endogenous (DAG) or exogenous (PMA, bryostatin 1) nature. Treatment of LNCaP 
prostate cancer cells with PMA resulted in apoptosis. However, application of a 
different C1 ligand, bryostatin 1, did not induce apoptosis. More importantly, 
bryostatin 1 blocked PMA induced apoptosis, as it prevented the PMA-induced 
release of TNFα. Of all DAG-reponsive PKC isozymes in LNCaP cells PKCδ was 
shown to be critical for the induction of apoptosis and release of TNFα. Translocation 
to the plasma membrane of this PKC isozyme is required for the PMA-induced 
release of TNFα from this cell line. The data presented here show that bryostatin 1 
prevented proper translocation of PKCδ, but not of PKCα or PKCε, by PMA. Thus, 
PKCδ acts as a master regulator of apoptosis and is misdirected by bryostatin 1, 
thereby preventing PMA-induced apoptosis. In addition, PKCs are involved in the 
regulation of transcription. In the first comprehensive evaluation of transcriptional 
dynamics in response to PMA in the present study microarray analysis revealed
distinct roles of PKC isozymes during normal growth and apoptosis. Furthermore, it 
was shown how signaling molecules affect expression patterns and novel 
downstream targets of PKCδ were identified that are directly involved in apoptosis. 
On the basis of these results it is tempting to speculate that loss or dysfunction of 
PKCδ contributes to the diminished apoptotic response of prostate cancer cells and 
that restoration of PKCδ might be of therapeutic benefit. In addition, the results
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indicate that bryostatin 1 may have limited effectiveness in the treatment of prostate 
cancer in humans.
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ABTS 2,2?-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)
ADP Adenosine-5'-diphosphate
AIDS Acquired immune deficiency syndrome
Akt 1 v-akt murine thymoma viral oncogene homolog 1
ANOVA Analysis of variance 
Apaf-1 Apoptotic protease activating factor-1
ATM kinase Ataxia-telangiectasia mutated kinase
ATP Adenosine-5'-triphosphate
BAD BCL-2 antagonist of cell death
BAK BCL2-antagonist/killer 1
BAX BCL2-associated X protein
BCL-2 B-cell-lymphoma-2
BCL2A1 BCL2-related protein A1
BCL-B BCL2-like 10
BCL-W BCL2-like 2
BCL-XL BCL2-like 1
BH3 BCL-2 homology 3
BID BH3-interacting domain death agonist
BIK BCL-2-interacting killer
BIM BCL-2-like-11
BMF BCL-2 modifying factor
BOK BCL-2-related ovarian killer
BRCA1 Breast cancer 1
bryo1 Bryostatin 1
BSA Bovine serum albumine
C1-4 domain Conserved domain 1-4
CARD Caspase-recruitment domain
Chx Cycloheximide
CM Conditioned medium
CTL Cytotoxic T lymphocytes
DAMP Danger-associated molecular pattern
DAG Diacylglycerol
DAPI 4???-Diamidin-2-phenylindol
DEAE-Dextran Diaminoethyl-Dextran
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DISC Death-ligand induced signaling complex
DMSO Dimethylsulfoxide
DNA Deoxyribonucleic acid
cDNA Complementary DNA or copy DNA
dNTP 2'-Deoxynucleoside 5'-triphosphate
DSB Double strand break
EDTA Ethylenediaminetetraacetic acid
EMT Epithelial-to-mesenchymal transition
EGFP Enhanced green fluorescent protein
EGFR Epidermal growth factor receptor
ELISA Enzyme-linked immunosorbent assay
ERK Extracellular signal-regulated kinases
FADD As-associated death domain protein
FAM (6-FAM) 6-Carboxyfluorescein
Fas TNF receptor superfamily, member 6
FasL Fas ligand
FBS Fetal bovine serum
FDR False recovery rate
Fig. Figure
FW primer Forward primer
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
GCRMA GeneChip Robust Multiarray Averaging
GO Gene Ontology biological processes
GPCR G-Protein-Coupled Receptor
GrA Granzyme A
GrB Granzyme B
h Hour(s)
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
H3K4me Methylated histone H3 lysine 4
HMGB1 High mobility group protein B1
HRK Harakiri (also known as death protein -5)
HRP Horseradish peroxidase
HSP70 Heat shock protein 70
IP3 Inositol-1,4,5-trisphosphate
JNK Mitogen-activated protein kinase 8
LB Lysogeny broth
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log Logarithm
LSD1 Lysine specific demethylase 1
MAP Kinase Mitogen-activated protein kinase
MAPKK Mitogen-activated protein kinase kinase
MCL1 Myeloid cell leukemia sequence 1
MEK Same as MAPKK
MES 2-(N-morpholino)ethanesulfonic acid
MGB probe Minor groove binder probe
myr Myristoylated
NB-ARC Same as NOD
NK Natural killer (cells)
NLS Nuclear localization signal
NOD Nucleotide-binding and oligomerization domain
N.R. Not represented
OG Oncogenesis
p Phospho
P Proliferation
PAI-2 Same as SERPINB2
PBS Phosphate buffered saline
PCA Prinicipal component analysis
PCR Polymerase chain reaction 
qPCR Quantitative PCR
qRT-PCR Quantitative RT-PCR
RT-PCR Reverse transcriptase real-time PCR
PDK1 3-phosphoinositide-dependent protein kinase-1
PEP005 Ingenol-3-angelate
PIN Prostate intraepithelial neoplasia
PI3K Phosphoinositide 3-kinase
PIP2 Phosphoinositol-4,5-bisphosphate
PKC Protein kinase C
aPKC Atypical PKC
cPKC Classical PKC
nPKC Novel PKC
PLC Phospholipase C
PMA Phorbol 12-myristate 13-acetate
PP2A Protein phosphatase 2A
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PPP1R15A Protein phosphatase 1, regulatory (inhibitor) subunit 15A
PS Pseudosubstrate sequence
PTEN Phosphate and tensin homolog 1
PUMA BCL-2 binding component-3
PVDF Polyvinylidenfluoride
RB1 Retinoblastoma 1
RISC RNA induced silencing complex
RNA Ribonucleic acid
dsRNA Double-stranded RNA
mRNA Messenger RNA
miRNA MicroRNA
rRNA Ribosomal RNA
siRNA Small interfering RNA
RNase Ribonuclease
RNAi RNA interference
RNP Ribonucleoprotein particle
RPMI medium Roswell Park Memorial Institute medium
RT Reverse transcription
RV primer Reverse primer
SAPK Mitogen-activated protein kinase 9
SDS Sodium dodecyl sulfate
SDS-PAGE SDS- polyacrylamide gel electrophoresis
S.E.M. Standard error of the mean
SERPINB2 Plasminogen activator inhibitor-2
S.O.C. Super optimal broth + glucose
SPP Sphingosine-1-phosphate
SSPE Sodium chloride, sodium phosphate (monobasic), 
ethylenediaminetetraacetic acid
SPHK Sphingosine kinase
ST Signal transduction
TACE/ADAM17 TNFα converting enzyme
TAE Tris-Acetate-EDTA
TBS-T Tris-Buffered Saline Tween-20
TF Transcription factors
TM Transmembrane domains
TNFα Tumor necrosis factor-α
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hTNFα Human TNFα
TPA 12-O-tetradecanoylphorbol-13-acetate (same as PMA)
TRAF Tumor necrosis factor receptor-associated factor
TRAIL TNF-related apoptosis-inducing ligand
Tris Tris(hydroxymethyl)aminomethane
V1-V5 domain Variable domain 1-5
vs. Versus
WD40 repeat beta-transducin repeat containing 40 amino acids , often 
terminating in a tryptophan-aspartic acid (W-D) dipeptide.
XIAP X-linked inhibitor of apoptosis
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